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Abstract
CHRISTY CASSARLY. Multistate Markov Models for Ordinal Functional Outcomes of
Acute Onset Disease: Application in Acute Stroke Therapy Trials. (Under the direction of
RENEE’ HEBERT MARTIN and YUKO Y. PALESCH)
The modified Rankin Scale (mRS), a seven-point ordinal scale ranging from no
symptoms to death, is the most commonly used outcome measures in acute stroke therapy
trials. Often, one visit is chosen for the primary analysis, and the scale is dichotomized
leading to loss of information. Recently, alternative methods for analyzing the mRS have
been explored. In addition, acute onset conditions require immediate attention and
treatment, posing a challenge to assess baseline outcome measures for clinical trials.
Thus, the mRS is not obtainable at baseline. Much of the progression or recovery
experienced by a patient suffering from an acute onset disease is expected to occur early
on. Moreover, typically, the goal of a treatment or therapeutic action is improvement in
patient health compared to their baseline measure. To accurately quantify improvement, a
measure of the outcome at baseline is ideal. This dissertation first explores the feasibility
of multistate Markov models for the analysis of the mRS which allow for the full ordinal
scale as well as the repeated measures data to be incorporated. The operating
characteristics (type I error and power) of the multistate Markov model are compared
with those from repeated logistic regression. Next, a framework is developed to predict
and incorporate the latent baseline mRS score in a piecewise-constant multistate model.
The last part of this work applies the piecewise-constant latent baseline model to real
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acute stroke trial data and compares the results with alternative methods for analysis of
the mRS.

ix

1 Introduction and Significance
1.1 Overview and Specific Aims
Ordinal response outcomes are often used in clinical trials. However, rather than
analyzing the full ordinal scale, many trials choose to dichotomize the primary outcome.
Although models used for dichotomous outcomes are easier to implement and tend to
produce

summary

statistics

with

more

clinically

meaningful

interpretations,

dichotomization can result in a loss of statistical power [1]. Additionally, in trials where
long-term follow-up is planned, the outcome is collected at multiple visits. Despite the
availability of the repeated measures, many trials focus the primary analysis on the data
from one visit, ignoring the additional outcome data.
One example of a therapeutic area that collects an ordinal outcome at multiple
visits in clinical trials is acute stroke therapy. For many such trials, the modified Rankin
Scale (mRS) score at 90 days post-randomization is used as the primary outcome
measure [2]. The mRS is a seven-point ordinal scale that ranges from 0 (no symptoms) to
6 (dead) and measures functional independence of stroke patients. It is commonly
dichotomized to test the primary hypotheses of interest.
An emphasis has been placed on exploring alternative analytic methods for the
analysis of mRS outcome data from acute stroke trials in recent years. Results indicate
that the original structure of the scale needs to be maintained in analysis as much as
possible [1, 3]. A number of alternative methods that preserve the ordinality of the mRS
have been proposed. However, these methods have not been widely accepted in practice.
1

The ultimate goal of a treatment or therapeutic action is to improve patient health
compared to their baseline measure at presentation, immediately following an event. To
accurately quantify improvement, a measure of the outcome at baseline would be ideal.
Conditions with sudden onset, such as stroke, require immediate attention and treatment,
posing a challenge to assess baseline outcome measures for clinical trials. Thus, the mRS
is not obtainable at baseline making the quantification of “improvement” very
challenging.
The multistate Markov model (MSMM) in continuous-time analyzes ordinal data
and has been used to model the course of many diseases [4]. These models are
advantageous in clinical applications where a disease process naturally moves through
increasing stages of severity [4]. The feasibility of MSMMs for analysis of the mRS has
not been previously considered. The mRS has more disease states (here, the seven levels
of the scale) than most clinical applications of MSMMs. Most of the subjects that
transition to a different state experience adjacent-state transitions, with only a few nonadjacent state transitions. The combination of these two issues leads to a data structure,
henceforth referred to as sparsely populated ordinal data, where small cell counts are
observed for transitions to non-adjacent states. Currently, there is little information
available regarding the appropriateness of MSMMs for sparsely populated ordinal
outcomes.
This dissertation aims to address the issues presented here, and the specific aims
of this research are as follows:
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1. To explore the operating characteristics (type I error and power) of MSMMs
compared with repeated logistic regression used to analyze sparsely populated
repeated measures ordinal data.
2. To develop a MSMM approach with piecewise-constant transition intensities that
incorporates a latent baseline state.
3. Analyze acute stroke therapy trial data using the methods developed in Aim 2 and
compare the results with those from alternative methods previously suggested for
the analysis of the mRS.
Realization of these aims will achieve the following: (1) feasibility of MSMMs
for sparsely populated ordinal data will be demonstrated through investigation of sample
size needed to achieve adequate power; (2) validity will be demonstrated through
simulation studies where type I error is preserved; (3) efficiency of inclusion of the
baseline mRS in the MSMM will be demonstrated; and (4) efficiency of the MSMM as
compared with other methods for ordinal outcome data will be shown.
1.2 Motivation and Clinical Relevance
Each year, approximately 795,000 people have a stroke, 87% of which are ischemic [5].
Most randomized trials in acute stroke neuroprotection treatment have failed to show
efficacy [3]. Several explanations have been proposed to describe the lack of positive
trials in stroke, including heterogeneity in stroke pathophysiology, poor methodological
and statistical standards, and incomplete preclinical testing [6]. One is poor study design
and statistical methods, specifically, the analysis of the primary outcome [1]. The models
that exist to fit dichotomous and continuous outcomes are easier to implement and tend to
3

produce summary statistics with more clinically meaningful interpretations. However,
analysis of ordinal response outcomes are less straightforward. Thus, traditionally, many
trials have dichotomized the ordinal mRS (Table 1.1) into success, scores of 0 or 1 (or 0
to 2), or failure, scores greater than 1 (or 2), for the primary analysis, often collected at 90
days post-randomization [7].
Table 1.1. Modified Rankin Scale.
Score Description
0
No symptoms at all
No significant disability despite symptoms; able to carry out all usual duties and
1
activities
Slight disability; unable to carry out all previous activities but able to look after
2
own affairs without assistance
3
Moderate disability requiring some help, but able to walk without assistance
Moderately severe disability; unable to walk without assistance and unable to
4
attend to own bodily needs without assistance
Severe disability; bedridden, incontinent, and requiring constant nursing care and
5
attention
6
Dead
Some patients with severe stroke may never have the potential to achieve a
“success” as defined by the dichotomy because they are so severely disabled at baseline.
Patients with minor strokes may achieve a successful score more easily than those who
are more disabled at baseline [8]. Thus, the prognostic heterogeneity of subjects does not
allow for potential equal contribution to the treatment effect estimation for all subjects
[9]. In general, ignoring these differences and dichotomizing the ordinal scale reduces
statistical power [1]. Any reduction in power may result in failure to find a clinically
meaningful treatment effect. In addition, the recovery and outcomes of subjects following
a stroke realistically lie on a continuum. Categorical analysis of the ordinal scale provides
4

a more comprehensive quantification of the process than the analysis of the dichotomized
scale [10].
An additional drawback of the traditional analysis - dichotomization of the 90 day
ordinal outcome - is the lack of use of available longitudinal data. Many acute ischemic
trials assess and collect the mRS score at discharge and/or at 30 days from randomization
and also at periodic intervals through 12 months, if long-term follow-up is planned in the
trial. However, the longitudinal data are rarely used in the primary analysis. A more
comprehensive clinical understanding of the treatment effect on outcome after a stroke
may be better described using repeated measures analysis if improvement or worsening is
expected beyond the 90 day primary outcome [11].
Recently, an emphasis has been placed on exploring alternative outcomes as well
as other analytic methods for the analysis of mRS data from acute stroke trials
(continuous analysis- t-test, linear regression; ordinal analysis- shift analysis,
proportional odds model, partial proportional odds model, adjacent categories logit
model; sliding dichotomy; utility weighted mRS; repeated measures analysis). The
literature indicates that the mRS should be analyzed in such a way that maintains the
original structure of the scale as much as possible [1, 3]. Alternative analytic strategies
proposed for analysis of the mRS have not been widely accepted in practice. These
strategies are reviewed in depth in the following section.
MSMMs are proposed to analyze the longitudinal mRS scores. An example of the
typical structure of the observed transition matrices for the mRS over time is provided in
Table 1.2. In this example, mRS outcome data from a mock acute stroke trial of 1,000
subjects are observed for four follow-up visits to illustrate the structure of sparsely
5

populated ordinal data. The transitions that occur from one visit to the next are presented
in each of the matrices.

mRS at Time 3

mRS at Time 2

mRS at Time 1

Table 1.2: mRS Transition Example.
0
0 84
1 45
2 12
3
2
4
1
5
0
6
0
Total 144
0
0 108
1 38
2
9
3
3
4
0
5
0
6
0
Total 158
0
0 126
1 21
2
5
3
0
4
0
5
0
6
0
Total 152

1
20
79
50
25
2
0
0
176

mRS at Time 2
2
3
4
5
6 Total
5
1
0
0
0 110
17 2
1
0
1 145
56 15 8
6
1 148
46 63 17 3
0 156
23 77 89 23 5 220
2
7 41 48 22 120
0
0
0
0 101 101
149 165 156 80 130 1000

1
26
123
31
5
1
0
0
186

mRS at Time 3
2
3
4
5
6 Total
5
3
1
1
0 144
12 2
0
1
0 176
86 18 2
1
2 149
32 116 8
1
0 165
4 34 102 13 2 156
0
2 18 45 15 80
0
0
0
0 130 130
139 175 131 62 149 1000

1
27
146
26
4
2
0
0
205

mRS at Time 4
2
3
4
5
6 Total
4
0
1
0
0 158
14 4
1
0
0 186
93 12 2
1
0 139
28 129 11 1
2 175
0 25 94 7
3 131
0
1 10 34 17 62
0
0
0
0 149 149
139 171 119 43 171 1000
6

In this example it is clear that the majority of subjects actually stay in the same
state from one time period to the next as shown by the largest numbers along the main
diagonal. The second largest numbers are to adjacent states and very few to non-adjacent
states. For example, 79 of the 145 subjects that had mRS = 1 at Time 1 also had mRS = 1
at Time 2. Only 17 of the 145 subjects with mRS = 1 at Time 1 transitioned to mRS = 2
at Time 2. This is an example of an adjacent-state transition, one where a subject moves
from one state (mRS = 1) to an adjacent state (mRS = 2). The other adjacent-state
transition for mRS = 1 is the transition to mRS = 0. Throughout the table, a majority of
observations are of subjects that remain in the same state, or have the same mRS score
from one time to the next. Most of the subjects that transition to a different state
experience adjacent-state transitions, with only a few non-adjacent state transitions.
In order to assess the application of the MSMM and number of states modeled, a
literature review was conducted. Using the following keywords: multistate, Markov,
panel, clinical, application, continuous-time, and excluding the following words:
piecewise, non-homogeneous, inhomogeneous, semi-Markov, hidden Markov and
random effects, a total of 40 articles were identified. An article was excluded if (a) the
content was actually theoretical and there was no application, (b) it was a review with no
new content, (c) multistate models were referenced, flagging it for review but the models
were not actually fit, or (d) the models were actually discrete-time. Of the remaining 26
articles, 25 fit models to data with five or fewer states and two fit models to data with six
states [12-36]. One publication used a six-state model to analyze a dataset with much
more data than is typically collected in acute stroke trials- approximately 5,000 patients
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[37]. Thus, the feasibility of MSMM for analysis of sparsely populated ordinal data with
a large number of states is unclear.
Currently, there is little information available regarding the appropriateness of
MSMMs for sparsely populated ordinal outcomes with a large number of possible health
states, as observed in longitudinal mRS data from acute stroke trials. In this dissertation,
feasibility and operating characteristics of MSMMs applied to sparsely populated ordinal
data are examined. In addition, a method is proposed to incorporate the latent baseline
mRS score in longitudinal MSMMs. The mRS is unavailable at baseline and the
aforementioned analytic techniques used for mRS data have adjusted for baseline severity
using the National Institutes of Health Stroke Scale (NIHSS), a score that ranges from 0
(no neurological deficit) to 42. Inclusion of the latent baseline mRS predicted using the
baseline NIHSS and other baseline covariates in a MSMM could improve statistical
efficiency to detect a significant treatment effect.
1.2.1 Motivating Examples
Data from two randomized double-blind, placebo-controlled acute stroke therapy trials
are considered. The NINDS tissue plasminogen activator (t-PA) trial was designed to
compare t-PA versus placebo in patients with acute ischemic stroke. The trial had two
parts. Part 1 tested whether patients treated with t-PA had early improvement, as
compared with those that were given placebo [38]. Part 2 was designed to determine
whether there was a consistent and persuasive difference between the groups tested using
four outcomes (Barthel Index, mRS, Glasgow Outcome Scale, and NIHSS) at 90 days
modeled as a Global Test Score [39]. The Barthel Index is an index of independence that
8

scores the ability of patients to care for themselves [40]. Patients that can perform all
assessed activities with complete independence are given a score of 100. The Glasgow
outcome scale is a global assessment of function that ranges from 1 indicating good
recovery to 5, death [41]. In order to be considered for inclusion for enrollment, there had
to be deficiency measureable by the NIHSS. A total of 624 subjects were enrolled (291 in
Part 1 and 333 in Part2), 312 in each group [38]. In Part 1, a benefit was observed for
patients treated with t-PA in all four outcome measures. The primary analysis in Part 2,
using generalized estimating equations, showed a significant global test score for the four
outcomes [39]. Clinical and demographic characteristics can be found in the original
paper [38].
The Albumin in Acute Stroke (ALIAS) trial was a two part trial designed to
compare 25% human serum albumin (ALB) and saline in patients with acute ischemic
stroke. Part 1 consisted of two separate, concurrently implemented trials designed to
assess whether ALB therapy improved neuroprotection beyond standard of care in two
cohorts of patients [42]. One cohort consisted of subjects that received standard
thrombolytic therapy (intravenous t-PA, intra-arterial t-PA, endovascular mechanical
thrombolysis or a combination of intravenous and endovascular treatment) and the other
was subjects who were not thrombolysed. Part 1 was suspended for safety reasons after
434 subjects (207 albumin and 217 saline) were enrolled. More patients died in the first
30 days in the ALB group than the placebo group and deaths were increased in patients
older than 83 years and patients that received excessive intravenous fluids. The study
design for Part 2 was modified based on the safety findings in Part 1. The primary
endpoint was a composite outcome defined as a NIHSS 0-1 and/or mRS 0-1 at 90 days
9

from randomization. Only patients with a baseline NIHSS of 6 or above were eligible for
enrollment in the trial. Part 2 was stopped early for futility after 841 subjects were
randomized (422 to albumin and 419 to saline). Clinical and demographic characteristics
are described elsewhere [43].
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2 Background
2.1 Previous Analytic Methods for Ordinal Outcomes
In this section, alternative analytic approaches to dichotomized analysis for the mRS are
explored. A summary of all of the methods is provided in Table 2.1.
2.1.1 Continuous Analysis
In general, analysis of continuous variables with the t-test and linear regression is
straightforward and produces clinically intuitive summary statistics. When these methods
are applied to ordinal scales, the results are less interpretable. Non-integer values from an
ordinal scale do not have a clear meaning when they are considered to be continuous.
When compared to ordinal analysis, continuous analysis has been shown to have
comparable power; however, the normality assumption is not met in most studies of
stroke outcome [3]. In order to consider an ordinal outcome to be continuous, the sample
size must be large enough for the normal approximation to be valid. Even in large
datasets, the mRS is skewed and there are no recommendations on how to normalize it.
2.1.2 Shift Analysis
The Cochran-Mantel Haenszel (CMH) shift test, or the van Elteren test, can be used to
analyze the distribution of ordinal data [7]. This test can show whether a treatment causes
a significant favorable shift toward better outcome. Shift analysis can account for ordered
categories, has no distributional assumptions and is easy to implement. However, it is not
feasible for large scale clinical trials with non-simple randomization schemes as it only
allows for a limited number of covariates. Logistic regression can be used in conjunction
11

with the shift analysis to provide an estimate of treatment effect because there is not an
associated odds ratio (OR) or effect size produced from the CMH test [44].
2.1.3 Ordinal Analyses
The proportional odds model (POM) assumes an identical effect of the predictors for
each cumulative probability [45]. In other words, the OR comparing treatment to placebo
in patients with mRS of 0 versus 1-6 is assumed to be the same as the OR for mRS of 0-1
versus 2-6, and so on. If the proportional odds assumption holds, statistical power can be
increased compared to analysis using a strict dichotomy. If the assumption fails, this
analysis could mask important effects at one end of the ordinal outcome [46]. The score
test for assessing the proportional odds assumption is anticonservative and DeSantis and
colleagues illustrated the lack of power of the score test using the data from the NINDS tPA trial [46]. The score test failed to reject the assumption of proportional odds (p =
0.06); however, a plot of the cumulative log odds of each mRS score for each treatment
group indicated that the assumption may be inappropriate.
The partial proportional odds model (PPOM) can be used when the proportional
odds assumption does not hold [46]. In general, there are two types of PPOMs, an
unconstrained and a constrained model [47]. The unconstrained PPOM produces cut-off
point-specific odds ratios. Alternatively, if a pattern is expected in the cut-off pointspecific odds ratio, for example a linear trend, constraints could be placed on the
parameter to obtain an appropriate fit. A linear trend occurs when the violation of the
proportional odds assumption is in one direction. This model includes an additional
parameter that allows for the ORs to increase proportional to the outcome scale. One
12

drawback of this model is that it could require a larger sample size to be adequately
powered.
The adjacent categories logit model (ACAT) is another logistic regression model
that does not require the proportional odds assumption. These models utilize singlecategory probabilities rather than cumulative probabilities [45]. Rather than effects that
refer to the entire response scale in the POM, the ACAT effects refer to the effect of a
predictor on the response in any two adjacent categories. As with the PPOM, the ACAT
model may require a larger sample size to be adequately powered to detect a treatment
effect.
2.1.4 Sliding Dichotomy Analysis
The sliding dichotomy (or the more generalized sliding trichotomy or tetrachotomy)
allows for the definition of success to vary based on patient-specific baseline prognostic
variables while maintaining a dichotomized outcome [48]. Re-analysis of acute stroke
therapy trials uses pre-specified cut-points for prognosis group definition based on the
NIHSS score [49]. The sliding dichotomy can be used to define “mild”, “moderate”, and
“severe” stroke using the baseline NIHSS score and defines “success” for each of the
three groups. One example is to define favorable outcome as mRS = 0 for mild strokes,
mRS = 0-1 for moderate strokes and mRS = 0-2 for severe strokes. Since baseline
severity is such a strong predictor of outcome in stroke patients, this baseline severity
adjusted approach has been considered for use over the traditional dichotomy [48].
Some simulation studies have shown that the utilization of the sliding dichotomy
provides higher sensitivity to detect true treatment effects [50]. For example, when the
13

probability of favorable outcome is high (greater than 0.5), the sliding dichotomy
provides higher power [9]. This is not a general result; however, as other studies have
determined that the traditional dichotomy is more powerful than the sliding dichotomy in
most situations [51]. When the probabilities of favorable outcome are lower, the
traditional dichotomy is more powerful [9].
While the sliding dichotomy has the potential to be a powerful tool in some
settings, it also has limitations. Determining the number of prognostic groups to use is not
an obvious decision and can be difficult to justify. In addition, determining how to choose
the cut points for the different groups can be a difficult task. Although using three groups
(mild, moderate and severe) is used in the literature [48], methods used to determine
severity cut points vary and need to be verified. Poor selection of the number of groups
and cut points could result in a loss of power. In addition, while the sliding dichotomy
allows for a baseline severity adjusted outcome, it still ignores any non- “success”
transition from one mRS score to another even though each mRS category (except 5 to 6)
represents a clinically meaningful difference in health state [52].
2.1.5 Utility-Weighted mRS
A recently proposed approach to transform the mRS into a patient-centered outcome
measure is the utility-weighted mRS (UW-mRS) [53]. The chosen patient-centered
outcome measure, utility, is the desirability of a specific health outcome to a patient [54].
Utility weights for each level of the mRS were derived by averaging values derived in
two prior studies. The first study mapped mRS scores to the European Quality of Life
Scale (EQ-5D) in transient ischemic attack survivors from a population-based study in
14

Great Britain [55]. The second study derived weights using the methodology of the
World Health Organization Global Burden of Disease Project [56]. Using the utility
weights is straightforward, and the UW-mRS is analyzed using continuous analysis.
Although this method is easy to implement and may provide greater statistical power, it is
based on only two populations and may not be generalizable to other populations. In
addition, the utility values are limited with respect to interpretation compared to other
methods.
2.1.6 Longitudinal Analysis
Generalized estimating equations (GEE) can be used to estimate parameters for outcomes
collected at multiple time points [57]. This approach allows for covariate adjustment
while incorporating within-patient correlation. GEE analysis has been used to analyze the
repeated measures of the mRS [11, 58]. Analysis of the longitudinal dichotomized
outcomes yields clinically meaningful odds ratios. However, as the models increase in
complexity, computational issues may arise.
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Table 2.1. Summary of statistics obtained from each type of analysis of the mRS.
Method
Statistic(s)
Interpretation
Strengths
Logistic
Odds ratio
The odds of good outcome in
 Easy to apply
regression
(OR)
the treatment group versus
 Easy to interpret
placebo
 Clinically intuitive
Linear
Difference
Improvement of the average
 Easy to apply
regression
of means
mRS score in patients that
received treatment
Shift analysis
Probability
The treatment group shifted in a  Easy to apply
(CMH test)
value
favorable direction toward a
 Accounts for ordered categories
better mRS score versus
 No distributional assumptions
placebo
POM
Summary
The odds of a lower mRS the
 Easy to apply
OR
treatment group versus placebo  Clinically meaningful summary
odds ratio
PPOM
ORs for six
Treatment has a significant
 Does not require proportional
dichotomies benefit for certain definitions of
odds assumption
of mRS
good outcome
ACAT
ORs for six
The treatment group is more
 Does not require proportional
adjacent
likely to have smaller mRS for
odds assumption
categories
certain adjacent mRS scores
Logistic
OR
The odds of good outcome
 Easy to apply
regression of
(defined by baseline severity)
 Easy to interpret
sliding
in the treatment group versus
 Clinically intuitive
dichotomy
placebo
Linear
Difference
Improvement of the average
 Easy to apply
regression of
of mean
utility score in patients that
 Can increase power
UW-mRS
utility scores received treatment
Repeated
OR
The odds of good outcome over  Utilizes all longitudinal data
measures GEE
the 12-month period in the
 Clinically meaningful odds ratio
(dichotomized)
treatment group versus placebo
MSMM
Hazard
The hazard (instantaneous risk)  Utilizes full ordinal scale
ratios for
of transitioning from one mRS
 Utilizes all longitudinal data
each
state to another in the treatment  Estimates transition rates for
allowable
group versus placebo
progression and recovery
transition

Limitations
 Can result in a loss of power
 Requires prespecification of expected
treatment distribution
 No straightforward interpretation
 Normality assumption is often not met
with no recommendations for normalizing
 Accommodates a limited number of
covariates
 Not clinically intuitive- no effect size or
odds ratio
 May yield biased estimate if proportional
odds assumption is not met
 Anticonservative score test
 Less straightforward summary odds ratios
 Can require a larger sample size to be
adequately powered
 Can require a larger sample size to be
adequately powered
 Less power in some scenarios
 Choosing groups and cut-points poorly
leads to loss of power
 May not be generalizable to other studies
 Limited interpretability
 More complicated modeling
 May have computational difficulties
 Difficulty in estimating sample size
 Computationally intensive

2.2 Multistate Markov Models
2.2.1 General Multistate Markov Models
MSMMs are an alternative approach to analyze repeated measures data with an ordinal
outcome. These types of models describe how a process moves between states over time,
which is desirable in the description of disease processes that naturally move through
increasing stages of severity [59]. MSMMs can provide a better clinical understanding of
the disease process since the information from the entire course of the disease is used to
estimate the parameters of the model. These models have been used in numerous clinical
applications including: multiple sclerosis [60], periodontal disease [61], alcoholism [62],
and psychiatry [63].
Figure 2.1 represents a general MSMM with four states. The arrows indicate that
a transition can occur between any two states. The model estimates parameters describing
each of the allowable transitions.

Figure 2.1: General four-state MSMM.
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The use of MSMMs requires that the Markov property holds for the observed
data. Consider a system with a finite state-space   {1, 2,3,..., I } , where I represents
the number of states. Let X (s  t ) be a discrete random variable that indicates the state
occupied by the system at time s  t . Let FX ( s )  { X (v) : v  s} which denotes all
information pertaining to the history of X up to time s [64]. A series of observations
has the Markov property if the conditional distribution of X (s  t ) given FX ( s ) , satisfies

P  X (s  t )  j | FX ( s ) , X (s)  i  P  X (s  t )  j | X (s)  i  pij (s, t ), i, j  (2.1)
In other words, the present state depends only on the immediately preceding observation
and not on the ones that precede it.
MSMMs may be defined for both discrete time and continuous. Although the
course of disease is a continuous process, clinical trials often only collect data at
intermittent follow-up visits. In the context of stroke, the exact time of progression or
recovery, or change of state, of disease is not observed. Data of this type, representative
of a continuous process yet observed at discrete time points, is referred to as panel data
[65]. Both discrete and continuous time MSMMs can be used to describe panel data. In
many acute stroke trials, the mRS is collected at follow-up visits that are not evenly
spaced. In such instances, continuous time models are appropriate. A continuous model
for panel data can only be used in cases where the sampling times are considered to be
non-informative [66]. An example of non-informative sampling is a fixed observation
scheme, where the interval of follow-up is specified in advance. However if observations
are not fixed or random and are self-selected by the subject (informative), this modeling
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technique is not appropriate without properly adjusting for the additional information
[66]. For instance, these models cannot be used in a scenario where observations occur
when a subject visits a doctor because they are in poor-condition. A model that
incorporates the information from the sampling times must be used for this type of selfselected follow-up outcome data. In acute stroke trials, the follow-up visits are usually
specified in advance and are non-informative so continuous modeling is appropriate.
A common assumption of continuous-time MSMMs is that of homogeneity,
where transition probabilities remain constant over time. When homogeneity is assumed,
the transition probabilities, pij (t ) , are defined as
pij (t )  P{ X (s  t )  j | X (s)  i}  P{X (t )  j | X (0)  i} .

(2.2)

Since this expression does not depend on s , the transition from state i to state j on a
time interval of length t has the same probability at any time. The pij (t ) are elements of
the transition probability matrix, P(t ) .
In order to construct continuous time Markov chains, the amount of time the
process will remain in a state, i  must be determined. Suppose X (0)  i and let Ti
represent the amount of time a process stays in i after entering. To derive the distribution
of Ti , let s, t  0 and consider
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Pr{Ti  s  t | Ti  s}
 Pr{ X (r )  i for r  [0, s  t ] | X (r )  i for r  [0, s]}
 Pr{ X (r )  i for r  [ s, s  t ] | X (r )  i for r  [0, s]}
 Pr{ X (r )  i for r  [ s, s  t ] | X ( s)  i}
(Markov property)
 Pr{ X (r )  i for r  [0, t ] | X (0)  i}
(time homogeneity)
 Pr{Ti  t}.
Thus Ti satisfies the memoryless property and follows the exponential distribution.
The movement of a subject between states is described by ij , the transition
intensities:

ij  lim

 t 0

P( X ( t )  j | X (0)  i)
, for i  j .
t

(2.3)

The intensities represent the instantaneous rate of moving from state i to state j  i and
form the generator matrix, Λ , whose rows sum to zero and the diagonal entries are

ii   ij .
j i

In each of the continuous time Markov chain constructions only the local behavior
of the process is known. To determine the global behavior of the process, Kolmogorov
differential equations to solve for the terms

pij (t )  Pr{X (t )  j | X (0)  i} .
These are a system of ordinary differential equations describing the probabilities pij (t ) .
Two sets of Kolmogorov equations exist, forward and backward differential equations.
The forward differential equations are used when the interest is to understand a process at
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a future time. Backward differential equations are used to describe what happened at a
previous time given that a process has a certain state in the future. Using the ChapmanKolmogorov equation,


pik ( , t )   pij ( ,  ) p jk ( , t), where    t
j 1

the forward differential equations are derived as follows [67]:
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(2.4)

p'ij (t )  lim

pij (t  h)  pij (t )
h

h 0


1 k
 lim   piy (0, t ) p yj (t , t  h)  pij (t ) 
h 0 h
 y 1

k

1
 lim   Pr{ X (t )  y | X (0)  i}Pr{ X (t  h)  j | X (t )  y}  pij (t ) 
h 0 h
 y 1

1
 lim (Pr{ X (t )  j | X (0)  i}Pr{ X (t  h)  j | X (t )  j}
h 0 h
k





y 1, y  j

Pr{ X (t )  y | X (0)  i}Pr{ X (t  h)  j | X (t )  y}  pij (t ))

k

1
 lim  pij (t ) 1   ( j ) h  o(h)     piy (t )    ( y, j )h  o(h)   pij (t ) 
h 0 h
y 1, y  j


 pij (t ) 1   ( j )h   pij (t )o(h)

1

k
k
 lim 
h 0 h 
 piy (t ) ( y, j )h     piy (t )o(h)   pij (t ) 
 y 
y 1, y  j
 1, y  j

k
k

1
 lim  pij (t ) 1   ( j ) h     piy (t ) ( y, j )h     piy (t )o(h)   pij (t ) 
h 0 h
y 1, y  j
y 1


k

1
 lim  pij (t ) 1   ( j ) h     piy (t ) ( y, j )h   o(h)  pij (t ) 
h 0 h
y 1, y  j


k

1
 lim  pij (t ) 1   ( j ) h  1    piy (t ) ( y, j ) h   o(h) 
h 0 h
y 1, y  j


k

1
 lim   pij (t ) ( j )h    piy (t ) ( y, j )h   o(h) 
h 0 h
y 1, y  j


k

o( h) 
 lim   pij (t ) ( j )    piy (t ) ( y, j )  

h 0
h 
y 1, y  j


  pij (t ) ( j ) 
pij (t ) ( j ) 

k



y 1, y  j

k



y 1, y  j

piy (t ) ( y, j )

piy (t ) ( y, j ).

Using the fact that  (i) 

k



j 1, j i

 (i, j ) the generator matrix of the Markov chain, Aij , is

defined as follows
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 k
  (i), if i  j    (i, j ), if i  j
Aij  
  j 1
.
 (i, j ), if i  j 
if i  j
 (i, j ),
The Kolmogorov equations can then be rewritten in terms of the generator matrix:

 pij (t ) ( j ) 

k



y 1, y  j

piy (t ) ( y, j )

 pij (t ) Ajj 

k



y 1, y  j

piy (t )Ayj

k

  piy (t )Ayj
y 1

 ( P(t ) A)ij
P '(t )  P (t ) A .

Finally, the system of equations can be solved

P(t )  P(0)etA  etA
tA
where e is the matrix exponential and P(0) is the identity matrix. The matrix

exponential is defined by

t A
e 
[59].
 0  !
tA



(2.5)

For simple models P(t ) can be calculated in terms of A algebraically. In more complex
cases, the Kolmogorov equations define a system of equations that cannot be solved
analytically. If the eigenvalues of A are distinct, eigen-decomposition can be used to
calculate P(t ) [68].
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Let B be a diagonal matrix consisting of the eigenvalues and C be a matrix with
corresponding eigenvectors as the columns. If distinct eigenvalues exist, C can be
inverted and A  CBC 1 , and
  t B
t (CBC 1 )
 C  
!
 0
  0  !


etA  

 1
tB 1
 C  Ce C [67].


(2.6)

The model parameters are estimated using maximum likelihood estimation with
numerical optimization. Once the parameters are estimated, the likelihood can be
calculated.
Suppose X is observed over t0  t1  t2  ...  tM . Let i0 , i1 , i2 , ..., iM be the
observed states over these time points. Then, the associated likelihood function is
M

L( | x)  P(X 0  i0 ) P( X t j  i j | X t j1  i j 1 )
j i

M

 P(X 0  i0 ) P( X t j t j1  i j | X 0  i j 1 )

(2.7)

j i
M

 P(X 0  i0 ) Pi j1i j (t j  t j 1 ) .
j i

Using equations (2.5) in (2.7), the likelihood reduces to

  (t j  t j 1 )k ( k )i j1i j
L( | x)  Pi 0   

k!
j 1 k  0

M
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,



(2.8)

where Pi 0 is the initial probability that the process is at i0 . For a series of observations

xz 0 ,..., xznz

at times

tz 0 ,..., tznz

for patients z  1,...N , with covariate vectors pi and

model parameters  , the log-likelihood is
N

nz

l ( )   log( pxi ( 1) xi (ti (
z 1 1

1)

, ti ;pi , )) [59].

(2.9)

Application of MSMMs requires the user to consider which transitions can
realistically occur in continuous time. When the states represent levels of disease severity
it is assumed that in order for a subject to travel from one state to a non-adjacent state, the
subject also had to travel through the intermediate states [59]. For example, if a transition
from state 3 to state 1 is observed, it is assumed that the subject traveled through state 2
at some point as well. Thus, in these applications, a reduced transition intensity matrix
where non-adjacent state intensities are fixed to equal zero should be assumed, with the
exception of transitions to death. If a state represents death it is called an absorbing state
since transitions from death cannot occur. Figure 2.2 displays a general continuous
MSMM for panel data where the states represent disease severity and state k is death. The
same methods for parameter estimation from the general model apply for this reduced
model.
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Figure 2.2: General MSMM for disease severity.

2.2.2 Piecewise-constant Multistate Markov Models
In the case of ischemic stroke occurrence and treatment, patients can get better or worse
very quickly during the acute phase immediately after occurrence. For this reason, the
time homogeneity assumption is expected to fail for the first transition, from the
predicted baseline to the first observed outcome which typically occurs at one week or
one month post stroke onset. Therefore, the assumption of homogeneity is relaxed and a
non-homogeneous model is considered.
The MSMM for panel data can be extended to accommodate piecewise-constant
intensity matrices for the non-homogeneous case [59]. Here, the transition probability
functions are dependent on s , and the transition matrix function is P(s, t )  ( pij (s, t )) .
The transition intensity functions are now defined by
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P( X (t   t )  j | X (t)  i)
, i, j  S , i  j .
 t 0
t

ij (t )  lim

(2.10)

The time-homogeneity assumption can be tested by using a likelihood ratio test to
compare the time-homogenous model to piecewise-constant models with different cutoff
times.
2.2.3 Predictors
The effect of a predictor, specifically treatment, is incorporated into the model as
transition intensity functions [69]. Let

z be a vector of observed predictors then

ij (t; z )  ij (t ) exp( z ' ij (t )), ij (t )  0

where ij (t ) is the parameter vector associated with the predictor vector

(2.11)

z

in the

transition between states i and j in time t . The transitional rates are represented by

ij (t; z ) at time t for the patients with vector z .
2.2.4 Application of MSMMs to the mRS
mRS data collected from acute stroke trials is used to demonstrate the aforementioned
MSMM methodology. Although MSMMs have been used to describe a number of
disease processes [60-63, 70], currently literature is lacking applications of these models
on data with a larger, i.e. more than four, number of states. With disease represented as
seven states the mRS is a good example of where the application can be expanded. Also
the mRS is collected at discrete time points, the disease process itself is not discrete, thus
it is an example of panel data. Two acute stroke clinical trials are used in this application,
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the NINDS t-PA trial and the ALIAS trial. In the NINDS t-PA trial, the observations
occurred at 7-10 days, 90 days, 180 days, and 360 days [38]. The mRS was collected at
30 days, 90 days, 180 days, 270 days, and 360 days for ALIAS [43]. Because the
observations are not evenly spaced a discrete model is not appropriate, and a continuoustime MSMM is used.
The states of this model represent the seven levels of the ordinal mRS scale. The
nature of the mRS and the follow-up schedule lead to a sparsely populated matrix of
observed transitions. Tables 2.2 and 2.3 show the state tables of the frequency of
transitions for NINDS t-PA and ALIAS, respectively. The rows represent the state to
which a subject begins, and the columns represent the state into which the subject
transitions. These tables include all transitions over the course of follow up. For example,
for the NINDS t-PA trial, there were 196 observations where the mRS for a subject was 0
for two consecutive time points (including from 7-10 days to 90 days, 90 days to 180
days and 180 days to 360 days).
As previously described, a large proportion of the observed pairs of the mRS are
for subjects that do not transition and remain in the same state. The transitions that do
occur are largely adjacent state transitions. Though non-adjacent state transitions are
observed, it is assumed that a subject passed through the intermediate states; the
transitions were not captured because the mRS was observed at discrete times. This data
structure is unlike data in published applications of MSMMs. First, most other models
have only three or four states; here, there are seven. Second, the frequencies for many of
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the transitions are sparse. The feasibility of MSMMs for this type of data needs to be
determined.
Table 2.2. Frequency of mRS Transitions in NINDS t-PA.
0
1
2
3
4
5
6
0
196
46
4
0
1
0
1
1
62
224
23
4
4
1
5
2
6
53
73
20
4
0
7
3
6
21
48
137
9
3
6
4
3
18
23
78
156
21
28
5
0
2
2
14
53
79
75

Table 2.3. Frequency of mRS Transitions in ALIAS.
0
1
2
3
4
5
0
524
98
13
6
3
1
1
158
542
85
19
4
0
2
31
175
432
53
7
1
3
7
48
150
417
43
4
4
1
7
28
136
391
37
5
0
1
0
7
60
100

6
2
2
3
5
9
23

In order to determine the feasibility of MSMMs for analysis of sparsely populated
ordinal data, the operating characteristics of MSMMs are compared with repeated logistic
regression in Chapter 3 of this dissertation. Once the feasibility is assessed, a MSMM
approach with piecewise-constant transition intensities incorporating a latent baseline
state is developed in Chapter 4. Finally, in Chapter 5, the methods developed in Chapter 4
are applied to acute stroke therapy trial data and are compared with results from the
alternative methods previously described.
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3.1 Introduction
Most randomized trials in acute stroke neuroprotection treatment have failed to show
efficacy for new interventions [3]. Mergenthaler and Meisel (2012) provide several
explanations to describe the lack of positive trials in stroke including heterogeneity in
stroke pathophysiology and incomplete preclinical testing [6]. Two of the explanations
cited by the Optimising Analysis of Stroke Trials Collaboration are inadequate study
designs and inappropriate statistical methods, specifically the analysis of the primary
outcome [1].
The modified Rankin Scale (mRS) score at 90 days post-randomization is a
commonly used primary outcome measure in Phase III clinical trials of acute stroke
therapy [2]. The mRS is a seven-point ordinal scale that measures degree of disability of
stroke patients (Table 3.1).
Table 3.1. Modified Rankin Scale.
Score Description
0
No symptoms at all
No significant disability despite symptoms; able to carry out all usual duties and
1
activities
Slight disability; unable to carry out all previous activities but able to look after
2
own affairs without assistance
3
Moderate disability requiring some help, but able to walk without assistance
Moderately severe disability; unable to walk without assistance and unable to
4
attend to own bodily needs without assistance
Severe disability; bedridden, incontinent, and requiring constant nursing care and
5
attention
6
Dead
Analyzing the mRS as an ordinal scale has only recently gained acceptance [1, 3,
46]. Many trials have chosen to dichotomize the mRS into success, scores of 0 or 1 (or 0
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to 2), or failure, scores greater than 1 (or 2), for the primary analysis [7]. Though models
used for dichotomous outcomes are easier to implement and some prefer the clinically
meaningful interpretations, dichotomization can result in a loss of statistical power [1]. It
is intuitive that some patients with severe stroke may never have the potential to achieve
a success as defined by the dichotomy. Thus, the prognostic heterogeneity of subjects
does not allow for potential equal contribution to the estimation of the treatment effect for
all subjects [9].
Recently, an emphasis has been placed on exploring alternate analytic methods
for the mRS outcome data from acute stroke trials. Results indicate that the mRS should
be analyzed in such a way that maintains the original structure of the scale as much as
possible [1, 3]. Linear regression and analysis of variance have been suggested to analyze
the mRS scale as a continuous variable. Although results from these models are generally
intuitive, the application to the mRS leads to summary statistics that will not have a clear
interpretation. Non-integer values from an ordinal scale do not have a clear meaning
when they are treated as continuous.
Another popular alternative method for mRS outcome data is sliding dichotomy
analysis. The sliding dichotomy method allows for the definition of success to vary based
on patient-specific baseline prognostic variables while maintaining a dichotomized
outcome [48]. Commonly, re-analysis of acute stroke trial data using the sliding
dichotomy defines pre-specified cut-points for prognostic group inclusion based on the
National Institutes of Health Stroke Scale (NIHSS) score [49]. The mRS is unavailable
immediately after randomization so models of acute stroke trial data often adjust for
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baseline severity using the NIHSS, a score that ranges from 0 (no neurological deficit) to
42. Often, three prognostic groups are defined using the baseline NIHSS for the sliding
dichotomy as ‘mild’, ‘moderate’, and ‘severe’ and the definition for ‘success’ differs for
each group. One example is to define favorable outcome as mRS = 0 for mild strokes,
mRS = 0-1 for moderate strokes and mRS = 0-2 for severe strokes. Since baseline
severity is a strong predictor of outcome in stroke patients, this baseline severity adjusted
approach has been considered for use over the traditional dichotomy.
While the sliding dichotomy has the potential to be a powerful tool in some
settings, it has limitations. Some simulation studies have shown that the utilization of the
sliding dichotomy provides higher sensitivity to detect true treatment effects [50]. For
example, when the probability of favorable outcome is high (greater than 0.5), the sliding
dichotomy provides higher power [9]. This is not a general result; however, as other
studies have shown that the traditional dichotomy is more powerful than the sliding
dichotomy in many situations [51]. When the probability of favorable outcome is lower,
the traditional dichotomy is more powerful [9]. In addition, determining the number of
prognostic groups to use is not an obvious decision and can be difficult to justify.
Moreover, determining how to choose the cut points for the different groups can be a
difficult task. Although the use of three groups (mild, moderate and severe) is common in
the literature, methods used to determine severity cut points vary and need to be verified
[48]. Poor selection of the number of prognostic groups and cut points could result in a
loss of power. Furthermore, while the sliding dichotomy allows for a baseline severity
adjusted outcome, it still ignores any non-‘success’ transition from one mRS score to
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another even though each mRS category (except 5 to 6) represents a clinically
meaningful difference in health state [52]. The recovery and outcome of subjects
following a stroke realistically lies on a continuum. Ordinal analysis of the mRS scores
can provide a more complete understanding of this process than analysis of the
dichotomized scale [10].
Recently, methods using the full ordinal scale have been demonstrated [3, 46, 71].
The proportional odds model is a cumulative logistic regression model that has been
proposed for analysis of mRS outcome data, Use of this model requires the assumption of
proportional odds- the odds ratio comparing treatment to control in subjects with mRS =
0 versus 1-6 is the same as the odds ratio for mRS = 0-1 versus 2-6, and so on. In data
where the proportional odds assumption does not hold, shift analysis, an assumption-free
ordinal test, can be used [7]. Shift analysis can be performed using the van Elteren test,
an extension of the two-sample Wilcoxon rank-sum test. Though shift analysis does not
require assumptions, it does not produce a summary statistic which is often desired by
clinicians. Alternatively, in cases where the proportional odds assumption is
unreasonable, the partial proportional odds model or adjacent categories logit model can
be used. The partial proportional odds model includes an additional term to allow for the
odds ratios to increase proportional to the outcome scale [46]. The adjacent categories
logit model calculates odds ratios for each adjacent category of response in relation to
covariates. Both of these models are more flexible than the proportional odds model but
lack a single summary statistic.
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An additional drawback of focusing the primary outcome on the 90-day time
point is the lack of use of available longitudinal data. Many acute stroke trials collect the
mRS at discharge and/or at 30 days from randomization and also at periodic intervals
through 12 months, if long-term follow-up is planned. The longitudinal data are not often
used in the primary analysis. Repeated measures analysis, which incorporates outcome
data from all follow-up visits, may provide a more comprehensive clinical understanding
of the treatment effect on outcome after a stroke [11].

mRS at time 1

0
0
84
1
45
2
12
3
2
4
1
5
0
6
0
Total 144

1
20
79
50
25
2
0
0
176

mRS at time 2
2
3
4
5
6 Total
5
1
0
0
0 110
17 2
1
0
1 145
56 15 8
6
1 148
46 63 17 3
0 156
23 77 89 23 5 220
2
7 41 48 22 120
0
0
0
0 101 101
149 165 156 80 130 1000

mRS at time 2

Table 3.2. mRS transition example.

0
0 108
1
38
2
9
3
3
4
0
5
0
6
0
Total 158

1
26
123
31
5
1
0
0
186

mRS at time 3
2
3
4
5
6 Total
5
3
1
1
0 144
12 2
0
1
0 176
86 18 2
1
2 149
32 116 8
1
0 165
4 34 102 13 2 156
0
2 18 45 15 80
0
0
0
0 130 130
139 175 131 62 149 1000

In this article, a novel approach using multistate Markov modeling is proposed for
the mRS scores. Multistate Markov modeling incorporates the longitudinal ordinal data
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and provides clinically relevant summary statistics to describe treatment effect. The mRS
has more disease ‘states’ (here, the seven levels of the ordinal response) than many
previously considered clinical applications of multistate Markov models. An example of
the typical data structure of the observed mRS could be illustrated in Table 3.2. In this
example, mRS outcome data from a mock acute stroke trial of 1,000 subjects was created
for three follow-up visits. The ‘transition’ from one state to another that occurred from
one visit to the next is described in Table 3.2. For example, 79 of the 145 subjects that
had mRS = 1 at time 1 also had mRS = 1 at time 2. Only 17 of the 145 subjects with mRS
= 1 at time 1 transitioned to mRS = 2 at time 2. This is an example of an ‘adjacent-state’
transition. Throughout the table, a majority of the observations are instances where the
subjects remained in the same state, or had the same mRS score from one time to the
next. Most of the subjects that transitioned to a different state display adjacent-state
transitions, with a limited number of non-adjacent state transitions.
A literature review conducted of an online database yielded a total of 40 articles
using the following keywords: multistate, Markov, panel, clinical, application,
continuous-time, and the following excluded words: piecewise, non homogeneous,
nonhomogeneous, inhomogeneous, semi Markov, hidden, random effects. An article was
excluded if (a) the content was actually theoretical and there was no application, (b) it
was a review with no new content, (c) multistate models were referenced, flagging it for
review but the models were not actually fit, or (d) the models were actually discrete-time.
Of the remaining 26 articles, 25 fit models to data with five or fewer states and two fit
models to data with six states [12-36]. One publication used a six-state model to analyze
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a dataset with much more data than is typically collected in acute stroke trialsapproximately 5,000 patients [37].
The multistate Markov model is introduced in Section 3.2. The main focus of the
paper is to approximate the power and type I error probabilities for multistate Markov
models of data structures similar to the longitudinal mRS outcomes observed in acute
stroke trials. In Section 3.2, continuous-time multistate Markov models are defined and
the simulation scenarios for estimation of the operating characteristics of these models
are described. In Section 3.3, the type I error probabilities and power are approximated
for varying design elements and power of the multistate models is compared with that of
repeated measures logistic regression. In Section 3.4, the findings are summarized and
discussed.
3.2 Methods
Multistate Markov modeling is an alternative approach to analyze repeated measures data
with an ordinal outcome. The multistate Markov model describes how a process moves
between states over time, which is desirable in the description of disease processes that
naturally move through increasing stages of severity [4]. Subjects can improve and
worsen over the course of follow-up and these movements back and forth between
disease states are all incorporated in the estimation of the model. Multistate Markov
models can provide a better clinical understanding of the disease process since the
information from the entire course of the disease is used to estimate the parameters of the
model. These models have been used in numerous clinical applications including:
multiple sclerosis [60, 70], periodontal disease [61], alcoholism [62], and psychiatry [63].
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This approach has not been used before for mRS data and therefore, in this article a
simulation study is performed to examine the operating characteristics of the proposed
approach.
3.2.1 Multistate Markov Models
The use of multistate Markov modeling requires that the Markov property holds for the
observed data. Consider a stochastic process with a finite state-space S  {1, 2,3,...I } ,
where I represents the number of states in the model. Let X ( s) be the state occupied at
time s . The series of observations has the Markov property if the conditional distribution
of X ( s  t ) , given FX ( s )  { X (v) : v  s} , where FX ( s ) denotes all of the information
pertaining to the history of X up to time s [64], satisfies

Pr  X (s  t )  j | FX ( s ) , X (s)  i  Pr  X (s  t )  j | X (s)  i  pij (s, t ), i, j  I .

(3.1)

In other words, a Markov process is one such that the conditional probability distribution
of the state of a process at a given time is dependent only on the immediately preceding
observation and not on the earlier ones.
Markov models may be defined for discrete time as well as continuous. Although
the course of disease is a continuous process, clinical trials often only collect data at
intermittent follow-up visits. In the context of stroke, the exact time of progression or
recovery, or change of state, of disease is not observed. Data of this type, representative
of a continuous process that is only observed at discrete time points, is known as panel
data [72]. Both discrete and continuous time multistate Markov models can be used to
describe panel data. If the sampling times are equally spaced, a continuous model that has
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been adapted for panel data is preferred over a discrete model [68]. In many acute stroke
trials, the mRS is collected at follow-up visits that are not evenly spaced. In such
instances, continuous time models are appropriate. A continuous model for panel data can
only be used in cases where the sampling times are considered to be non-informative [4].
An example of non-informative sampling is a fixed observation scheme, where the
interval of follow-up is specified in advance. However if observations are not fixed or
random and are self-selected by the subject (informative), this modeling technique is not
appropriate without properly adjusting for the additional information [4]. For instance,
these models cannot be used in a scenario where observations occur when a subject visits
a doctor because they are in poor-condition. A model that incorporates the information
from the sampling times must be used for this type of self-selected follow-up outcome
data. In acute stroke trials, the follow-up visits are usually specified in advance and are
non-informative so continuous modeling is appropriate.
A common assumption when fitting continuous-time Markov models is the timehomogeneity assumption. This is the assumption that the transition probabilities remain
constant over time. When time-homogeneity is assumed, the probability that the next
move of the process is from state i to state j can be written,
P{ X (s  t )  j | X (s)  i}  P{X (t )  j | X (0)}  pij (t ) .

(3.2)

Thus, the probabilities only depend on the length of the time interval, t . The pij (t ) are
elements of the transition probability matrix, P(t) . The (i, j ) th entry of P(t) is the
probability of being in state j given the starting state is i after a time interval of t .
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The movement of a subject between states is described by ij , the transition
intensities:
P( X ( t )  j | X (0)  i ) .
 t 0
t

ij  lim

(3.3)

The intensities represent the instantaneous rate of moving from state i to state j  i . The
intensities form the generator matrix, Λ , whose rows sum to zero and the diagonal
entries are ii  


j i

ij

. P(t) can be solved by taking a matrix exponential of Λ scaled

by the time interval,


t k Λk
P(t)  e  
k 0 k !
tΛ

(3.4)

where Λ k is the kth power of the generator matrix Λ .
Suppose now that we observe X over t1  t2  ...  tM . Let i1 , i2 , ..., iM be the
observed states over these time points. Then, the associated likelihood function is
M

P( X 1  i1 ) P( X t j  i j | X t j1  i j 1 )
j i
M

 P( X 1  i1 ) P( X t j t j1  i j | X 0  i j 1 )
j i

M

 P( X 1  i1 ) Pi j1i j (t j  t j 1 ) .
j i

Using (3.4) and (3.5), the likelihood is therefore
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(3.5)

  (t j  t j 1 ) k ( k )i j1i j
L( | x)  Pi1   

k!
j 1 k  0

M






(3.6)

where Pi is the initial probability that the process is at i1 .
1

The effects of covariates can also be investigated by modeling the intensity as a
function of the variables of interest, z(t) . The transition intensity matrix elements ij are
replaced by

ij  z  t    ij(0) e

ij' z(t)

where ij(0) represent the baseline intensities (without covariates) and

(3.7)

ij are the effect of

covariates on the transition from state i to state j [4]. To determine the significance of
a covariate, a likelihood ratio test is used to compare nested models. In Section 3.3, the
model including treatment is compared to a model without treatment. Thus, the resulting
intensities are

ij  ij(0) e

ij z ( t )

(3.8)

where ij(0) represent the intensities without the covariate and z (t ) is the treatment
assignment (0 for control and 1 for treatment) for subject n . Thus, the null and
alternative hypotheses for the test of the effect of treatment are

H 0 : ij  0 for all i, j
H1 : ij  0 for some i, j.
The null hypothesis will be rejected using the asymptotic distribution of 2ln( L0 / L1 )
where L0 is the maximum value of the likelihood of the reduced model and L1 is the
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maximum value of the likelihood of the full model. For large n , this asymptotic
distribution is a  2 with k degrees of freedom, where k is the difference in the
number of parameters in the two models.
The difficult part in this process is obtaining the maximum likelihood estimates.
Often methods such as Newton-Raphson can cause issues because the computation of the
second derivative can be costly in terms of time. Additionally, if the Hessian matrix is
non-negative definite away from the optimum, slow or non-convergence may occur. To
avoid this, other approaches have been proposed. The Broyden-Fletcher-GoldfarbShanno (BFGS) method is used to maximize the likelihood with analytic gradients and
can be used with or without analytic first derivatives [4, 68]. The BFGS algorithm
approximates Newton’s iterative method for finding the roots of differentiable functions
[73]. In this algorithm, the Hessian matrix of second derivatives is not evaluated directly.
Instead, it approximates the Hessian using gradients. If too many transitions are
considered with not enough data in a multistate model, the maximum likelihood estimate
could lie on boundary of the parameter space (when one or more transition intensities
equal 0). If this occurs, the maximum likelihood estimate may be inconsistent since
asymptotic theory requires the assumption that the true parameter value lies away from
the boundary.
It is important to consider which transitions can realistically occur in continuous
time. When the states represent levels of disease severity it is assumed that in order for a
subject to travel from one state to a non-adjacent state, the subject also had to travel
through the intermediate states. Thus, in this application of these models, a reduced
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transition intensity matrix where non-adjacent state transition intensities are fixed to
equal zero should be assumed. The exception is with mRS = 6, we assume that death can
occur from any state and transitions cannot occur out of it because it is an absorbing state.
The allowable transitions are displayed in Figure 3.1.

Figure 3.1: Multistate model for panel observed mRS data.

3.2.2 Simulation Scenarios
In this section, the procedures for examining the operating characteristics of multistate
Markov models under a variety of conditions are described. First, whether or not the
multistate Markov model preserves the type I error probability is examined through
simulations. Next, given the type I error probability, the desired power is examined for
two clinically relevant scenarios, each with two sets of follow-up trajectories for each of
the models. The power of the multistate Markov model is compared with that of repeated
logistic regression. The motivating example of this simulation study is the limited nonadjacent state transitions observed in mRS data. The simulation scenarios are generated
such that the assigned transition probabilities mimic real acute stroke trial as closely as
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possible. Data from three different phase III acute stroke trials were considered when
assigning transition probabilities.
The first trial used is the National Institute of Neurologic Disorders and Stroke
(NINDS) tissue-Plasminogen Activator (t-PA) study [38]. The NINDS t-PA trial
compared t-PA versus placebo in subjects with acute ischemic stroke. The primary
analysis showed a significant global test score for four (Barthel Index, mRS, Glasgow
Outcome Scale, and NIHSS) outcomes as well as for the mRS alone [39]. To further
illustrate the structure of acute stroke trial data, the mRS scores for the control and
treatment groups are displayed in Sankey plots in Figures 3.2 and 3.3 [74], respectively.
The Sankey plots allow for a visualization of changes within each treatment group over
time. The longitudinal bar chart shows the percentage of subjects with each mRS score at
each follow-up visit. In addition, the wavy lines between each bar, the links, describe the
change in the number of subjects in each state, over time. A thick line indicates that a
large number of subjects transition between two states. Note that as illustrated in Table
3.2 with the mock data, the percentage of transitions that occur between non-adjacent
states is small.
The other two trials considered for data generation were the albumin in acute
stroke (ALIAS) II trial and the Interventional Management of Stroke (IMS) III trial [43,
75]. ALIAS II was designed to compare 25% human serum albumin and saline in patients
with acute ischemic stroke. IMS III was designed to compare intravenous t-PA plus an
intra-arterial device therapy and/or additional intra-arterial t-PA versus t-PA alone. Both
ALIAS II and IMS III were stopped early for futility.
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Figure 3.2: Sankey plot of NINDS t-pa control group subjects over time.

Figure 3.3: Sankey plot of NINDS t-pa treatment group subjects over time.
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For each of the previously mentioned trials, the observed transition counts for
each follow-up visit are combined in one table to calculate aggregate observed transition
probabilities. To illustrate, data in Table 3.2 would be combined in an aggregate table
with 192 (84 + 108) instances where a subject stayed in state 0 out of the total 254 (110 +
144) instances where a subject started in state 0. Thus, for example, the observed
aggregate transition probability of remaining in state 0 is 0.76 (192/254), in the mock
trial. These observed transition probability matrices are calculated for each study to
illustrate the structure for mRS outcome data from acute stroke trials. As previously
mentioned, the notable characteristic of the mRS outcome data from these trials is the
limited number of non-adjacent state transitions.
To evaluate power, data are generated under the alternative hypothesis that a
treatment effect exists. In each multistate Markov model, multiple parameters describe a
single covariate effect. Therefore, there are many ways in which a significant treatment
effect could exist. In order to simplify, we consider two different clinically relevant
scenarios. The first scenario considers a case where only one of the assigned transition
probabilities differs between the control and treatment groups. For this set of simulations,
the transition probabilities are assigned such that they are all the same for both groups
except for the transition from mRS = 3 to mRS = 2 (as well as the transition from mRS =
2 to 1, mRS = 2 to 0, and mRS = 1 to 0, as the intermediate transitions may not be
observed). The second scenario for sample size estimation is one where the treatment
effect exists in all transitions. The positive transitions are assigned higher probabilities in

47

the treatment group, making them more likely. The negative transitions are assigned a
larger probability in the control group.
It is likely that other ordinal scales collected over time have a longitudinal
structure similar to the mRS, where non-adjacent state transitions are sparse. In order to
consider scales with differing numbers of states, we used the data generated to mimic the
mRS described above and collapsed the estimated transition probability matrices to create
six-, five-, and four-state models. The method in which the states are aggregated is
described in Table 3.3.
Table 3.3. Simulation scenarios for power.
Number of subjects per group
States Visits
One differing transition
All differing transitions
7
3
400, 500, 600, 800, 1000
300, 400, 500, 600, 800, 1000
6
200, 300, 400, 500, 600
125, 150, 175, 200, 300, 400
6
3
400, 500, 600, 800, 1000
300, 400, 500, 600, 800, 1000
6
150, 200, 300, 400, 500, 600
125, 150, 175, 200, 300, 400
5
3
300, 400, 500, 600, 800, 1000
200, 300, 400, 500, 600, 800, 1000
6
100, 150, 200, 300, 400, 500, 600
75, 100, 125, 150, 175, 200, 300,
400
4
3
200, 300, 400, 500, 600, 800, 1000 200, 300, 400, 500, 600, 800, 1000
6
100, 150, 200, 300, 400, 500, 600
50, 75, 100, 125, 150, 175, 200,
300, 400
3
3
200, 300, 400, 500, 600, 800, 1000 200, 300, 400, 500, 600, 800, 1000
6
100, 150, 200, 300, 400, 500, 600
50, 75, 100, 125, 150, 175, 200,
300, 400
In practice, collapsing states is a decision that should be made with caution. For
example, if there is clinical evidence that two health states are not distinct, it may be
acceptable to combine them. If two health states are aggregated that are vastly different
there could be a loss of power. In order to illustrate this point, for the 5-state (and
subsequently the 4-state) model, mRS = 2 and mRS = 3 are aggregated. In the scenario
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where only the transition from mRS = 3 to mRS = 2 differs, there is an expected loss in
power for these aggregated models. Thus, in the case where only one transition differs, an
additional scenario was considered where mRS = 2 and mRS = 3 are not combined,
referred to as the 5-state* model.
The probabilities used to assign outcome trajectories are listed in Appendices 3A3C. Using these probabilities, the data generation includes the following steps:
1. Generate a sample of treatment assignments from a random uniform(0, 1)
distribution where the probability that the m th subject is assigned to treatment is
0.5.
2. Generate random uniform variables for all t .
3. Assign a state for t  0 using the probabilities described in the appendices.
4. For each t  0 use the probabilities to assign a state conditional on the state
occupied at t  1 .
To determine the type I error, data are generated under the null hypothesis of no
treatment effect. The simulation scenarios for estimation of type I error include differing
number of states and increasing sample size per group, starting at 200.
The simulation studies for power are repeated for each set of simulation
parameters (Table 3.4) allowing the number of subjects in each treatment group to vary,
as well as the number of follow-up visits (three or six visits). Each set of simulations is
carried out using 1,000 runs. For each set of parameters the sample size is set to observe
approximately 80% power. The type I error for the multistate Markov model is set to the
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observed value from the previously described simulations. The resulting power is
compared to that of the repeated logistic regression model.
Table 3.4. Modified Rankin Scale inclusion categories.
Symbol
Model
mRS Scores
7 state mRS 0, mRS 1, mRS 2, mRS 3, mRS4, mRS 5, mRS 6
6 state mRS 0, mRS 1, mRS 2, mRS 3, mRS4, mRS 5-6
5 state mRS 0, mRS 1, mRS 2, mRS 3, mRS 4-6
4 state mRS 0, mRS 1, mRS 2-3, mRS 4-6
3 state mRS 0-1, mRS 2-3, mRS 4-6
The data used were simulated using SAS 9.4 statistical software. SAS 9.4 was
also used to run the Generalized Estimating Equation models for repeated measures
logistic regression with PROC GENMOD. The Markov models were fitted in R statistical
software version 3.3.0 using the ‘msm’ package for multistate Markov models [4].
3.3 Results
In this section, the behavior of the type I error and power is evaluated. The simulation
results of the type I error are displayed in Figure 3.4. For the application considered, with
data structured similar to the three acute stroke trials described in Section 3.2, the type I
error probability is preserved for all of the multistate Markov models. In order to examine
whether the chi-square approximation of the likelihood ratio test is appropriate for
comparing the nested models, p-values under the appropriate chi-square distribution were
obtained and are shown in Appendix 3D. The p-values appear to be approximately
uniform and the test-statistic sampling distribution approximates the chi-square
distributions quite adequately.

50

Figure 3.4: Graph of approximated type I error probabilities for models with three follow-up visits based on
1,000 simulations.

For considering power we need to set alternative hypotheses. There are many
potential alternative hypotheses so we consider two scenarios that are clinically relevant.
In the first scenario, transition probabilities are assigned such that the only difference
between treatment groups is in the transition from mRS = 3 to mRS = 2. The results with
three and six follow-up visits are displayed in Figures 3.5a and 3.5b, respectively. The
transition probabilities assigned for these simulations are presented in Appendix 3B. The
results indicate that for a seven-state model with three follow-up visits, approximately
500 subjects are needed in each group to obtain 80% power. There is a marginal increase
in power when states mRS = 4 and mRS = 5 are combined in the six-state model. When
mRS = 2 and mRS = 3 are combined for the original five-state model we see an extreme
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decrease in power. This is expected because the model was misspecified. The only
difference between treatment groups was in the transition from mRS = 3 to mRS = 2 so
when these two states are combined, there are virtually no differences to detect. The same
phenomenon is observed in the four-state model because the difference is still lost from
aggregating mRS = 2 and mRS = 3. If we consider the fact that the difference lies
between those two states and instead collapse mRS = 0 and mRS = 1 in the alternative
five-state model (5*) then we see another marginal increase in power. The observed
increases in power are expected because there are no differences in the two groups in the
aggregated states and there are fewer parameters to estimate in the model.
Figure 3.5b displays the approximated power in the scenario where only the
transition from mRS = 3 to mRS = 2 differs, now with six follow-up visits instead of
three. The results for the models with six follow-up visits are similar to those in the
models with three follow-up visits, except that the power is significantly increased. The
power for the seven-, six- and five-state* model are all very similar. Each of these models
requires approximately 150 subjects in each group to obtain 80% power. When mRS = 2
and mRS = 3 are combined in the five-state model (and subsequently in the four-state
model), there is an extreme loss of power, as previously observed.
The results of the power simulations in the second scenario, where the treatment
effect exists for all transitions, are displayed in Figures 3.5c and 3.5d. The assumed
transition probabilities are described in Appendix 3C. The approximate power for the
three follow-up visit case is displayed in Figure 3.5c. In the six- and seven- state model,
the iteration to obtain the estimates do not converge for sample sizes as small as 200.
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There are negligible differences in power between each of the models. Since there are
differences in all transitions, there will be some loss of power by aggregating states.
However, there is a gain in power with fewer parameters in a reduced model. These two
facts lead to very minimal change in power. For any given model with three follow-up
visits in this scenario, approximately 600 subjects are needed per group to attain 80%
power.

Figure 3.5: Graph of approximated power based on 1,000 simulations.

Figure 3.5d displays the approximated power where all assumed transition
probabilities differ between groups and the number of follow-up visits is increased from
three to six. As observed in the first scenario, the results from the models with six follow53

up visits are similar to those from the models with three follow-up visits, with a
significant increase in power. The increase in power is expected since there are twice as
many observation per subject contributing to the estimation of the model parameters. In
this case, approximately 250 subjects are needed per group to reach 80% power.
Table 3.5. Comparison of power for models with three follow-up visits.
Multistate Markov models
N per Logistic
van
Scenario group regression Elteren 7-state 6-state 5-state 4-state 3-state
2 to 1 only 200
0.257
0.117
0.206 0.256
300
0.371
0.138
0.544 0.283 0.349
400
0.469
0.193 0.635 0.663 0.670 0.381 0.468
500
0.573
0.222 0.753 0.771 0.787 0.499 0.544
600
0.646
0.224 0.837 0.848 0.870 0.567 0.626
800
0.743
0.267 0.926 0.939 0.956 0.703 0.760
1000 0.853
0.334 0.974 0.981 0.989 0.815 0.868
All shifts

200
300
400
500
600
800
1000

0.735
0.893
0.960
0.988
0.996
1.000
1.000

0.741
0.898
0.970
0.983
0.997
1.000
1.000

0.582
0.694
0.811
0.875
0.961
0.989

0.629
0.763
0.863
0.943
0.982
0.998

0.405
0.563
0.723
0.811
0.897
0.971
0.990

0.358
0.508
0.615
0.733
0.814
0.911
0.975

0.470
0.643
0.765
0.879
0.933
0.977
0.996

The approximated power from the models displayed in Figure 3.5 is compared
with that from repeated logistic regression in Tables 3.5 and 3.6. Table 3.5 lists the power
for the models with three follow-up visits and Table 3.6 lists the power for the models
with six follow-up visits. Repeated logistic regression was performed using the
dichotomized mRS scores, where scores of 0 or 1 were defined as successes and scores
greater than 1 were defined as failures.
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Table 3.6. Comparison of power for models with six follow-up visits.
Multistate Markov models
N per Logistic
van
Scenario group regression Elteren 7-state 6-state 5-state 4-state 3-state
2 to 1 only 100
0.119
0.075
0.474 0.288 0.321
150
0.188
0.098
0.622 0.629 0.417 0.463
200
0.257
0.117 0.732 0.734 0.776 0.546 0.578
300
0.371
0.138 0.871 0.889 0.920 0.714 0.784
400
0.469
0.193 0.957 0.961 0.967 0.860 0.906
500
0.573
0.222 0.983 0.990 0.991 0.936 0.947
600
0.646
0.224 0.994 0.992 1.000 0.997 0.982
All shifts

50
75
100
125
150
175
200
300
400

0.246
0.350
0.463
0.523
0.602
0.687
0.735
0.893
0.960

0.241
0.357
0.476
0.519
0.642
0.690
0.741
0.898
0.970

0.579
0.688
0.735
0.809
0.945
0.985

0.673
0.754
0.827
0.901
0.975
0.994

0.419
0.540
0.659
0.732
0.794
0.847
0.968
0.992

0.210
0.358
0.434
0.521
0.598
0.662
0.751
0.906
0.981

0.326
0.485
0.584
0.725
0.806
0.867
0.915
0.984
0.997

When only one assigned transition probability differs between groups, in correctly
specified models, the multistate Markov model requires significantly fewer subjects than
the repeated logistic regression model to be adequately powered. When the multistate
model is misspecified, the repeated logistic regression is more powerful. When all
assumed transition probabilities differ between groups, the repeated logistic regression
requires fewer subjects per group to reach 80% power. When there are three follow-up
visits, the repeated logistic regression model only requires about 300 subjects per group
to be adequately powered, compared to 600 in the multistate model. In the six follow-up
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visit case, approximately 150 subjects are needed per group compared to 250 in the
multistate Markov model.
3.4 Summary and Discussion
The mRS, one of the most commonly used outcome measures in acute stroke trials, is
ordinal but is often dichotomized for analysis. The loss of information from
dichotomizing the ordinal variable was examined in this article. In addition, despite the
availability of multiple mRS scores over time in many trials, a single measurement is
often chosen for primary analysis. The additional information available from the
longitudinal data could add further efficiency to the analysis. Multistate Markov
modeling is presented here as an alternative analytic approach for ordinal outcomes
collected longitudinally. The multistate Markov model describes how a process moves
between states over time, which is desirable because it lends itself to clinically relevant
interpretations.
In this paper, we have considered time-homogenous continuous Markov
multistate models for mRS outcome data observed in phase III acute stroke trials.
Simulations demonstrated that the desired type I error probability is preserved for the
likelihood ratio test comparing a multistate Markov model including treatment to one
without. Power was examined for two different clinically relevant scenarios. The two
scenarios represented two diverse instances where a treatment effect exists. In the first
scenario all of the assigned transition probabilities were the same for the two treatment
groups except the transition from mRS = 3 to mRS = 2. The assigned treatment
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probabilities in the second scenario differed between the groups for all transitions,
representing a positive treatment effect for all shifts.
The key findings of the simulation studies could be summarized as follows:


When the only difference between the treatment groups in assigned transition
probabilities is from mRS = 3 to mRS =2,
o misspecification of the five-state (and four-state) multistate model
drastically decreases power as this masks the only difference between
groups, the transition from mRS = 3 to mRS = 2
o the multistate model yielding the highest power is the 5-state* model
where mRS = 4 and mRS = 5 are combined, as well as mRS = 0 and mRS
=1
o power is not drastically different for the seven- six- or five-state* Markov
model
o the multistate model, when correctly specified, is more powerful than
repeated logistic regression



When all assigned transition probabilities differ between groups,
o power is essentially equal for all four multistate Markov models
considered
o the repeated logistic regression models are more powerful than the
multistate Markov models



For both scenarios, and all combinations of states considered, increasing the
number of follow-up visits from three to six drastically increased power.
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We considered a case where two distinct states were combined to examine the
effects of misspecification. It is important to note that for a process that is truly Markov
on I states, a reduced-state model will not satisfy the Markov property [76]. The
sojourn time will be non-exponential for the merged states and bias can be expected
through the misspecification. This highlights the importance of correctly specifying
models when using the multistate Markov approach. A modified version of Akaike’s
criterion could aid in model selection [77].
We conclude that multistate Markov modeling can be a more efficient approach to
analysis of mRS data from acute stroke trials. There are situations where dichotomization
might not lose efficiency and may be more powerful than the multistate Markov model.
Depending on the observed data structure, either technique could be more powerful. In
every model, however, increasing the number of follow-up visits from three to six
dramatically improved the power to detect a treatment difference.
A limitation of this study is the computational intensity required to run the
simulations. For the scenarios with a larger number of states, the time required to
complete the simulations was lengthy. Because of the time these simulations take, each
was only repeated 1,000 times. Larger simulation studies, say with 10,000 runs rather
than 1,000, would improve the precision on the estimates of the operating characteristics.
A second limitation of this study is the lack of effect size measurement. In order to
quantify an effect size, we would need to be able to define what outcome would be of
interest. For example, some previous studies have considered a 10% difference in
proportion of good outcome, where good outcome is defined by a dichotomized mRS
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scale. Quantification of the effect is not straightforward when using Markov multistate
modeling. This is a practical question to consider in the future.
A future direction of this work could be to compare the results of multistate
Markov modeling to repeated cumulative logistic regression. At the time of submission
the authors could not find any publications where longitudinal proportional odds models
or adjacent categories logit models were applied to mRS data. Interesting issues arise
about how to handle the proportional odds assumption and how to compare models when
the assumption fails. This may be a useful extension of the analysis of longitudinal mRS
data.
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3.5 Appendices
Appendix 3A: assumed transition probabilities for type I error simulations
In this appendix, we present Tables 3.1A-3.4A, which show the probabilities used to
determine the trajectories for the subjects in the type I error simulation study.
Table 3.1A. Assumed transition probabilities for the seven-state model.
Probabilities for time = 1
0
1
2
3
4
5
6
0.1000 0.1200 0.1300 0.1500 0.2300 0.1400 0.1300

0
1
2
3
4
5

0
0.8000
0.2000
0.0500
0.0200
0.0050
0.0005

Conditional Transition Probabilities for time > 1
1
2
3
4
5
0.1700 0.0200 0.0050 0.0030 0.0010
0.6800 0.0800 0.0200 0.0100 0.0050
0.2800 0.5400 0.1100 0.0100 0.0010
0.0800 0.2200 0.6000 0.0600 0.0050
0.0150 0.0600 0.2300 0.6000 0.0700
0.0070 0.0075 0.0450 0.2800 0.4800

Table 3.2A. Assumed transition probabilities for
the six-state model.
Probabilities for time = 1
0
1
2
3
4/5
6
0.100 0.120 0.130 0.150 0.370 0.130
Conditional Transition Probabilities for time > 1
0
1
2
3
4/5
6
0 0.800 0.170 0.020 0.005 0.004 0.001
1 0.200 0.680 0.080 0.020 0.015 0.005
2 0.050 0.280 0.540 0.110 0.011 0.009
3 0.020 0.080 0.220 0.600 0.065 0.015
4/5 0.003 0.011 0.034 0.138 0.714 0.100
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6
0.0010
0.0050
0.0090
0.0150
0.0200
0.1800

Table 3.3A. Assumed transition probabilities for
the five-state model.
Probabilities for time = 1
0
1
2/3
4/5
6
0.100 0.120 0.280 0.370 0.130
Conditional Transition Probabilities for time > 1
0
1
2/3
4/5
6
0
0.800 0.170 0.025 0.004 0.001
1
0.200 0.680 0.100 0.015 0.005
2/3 0.035 0.180 0.735 0.038 0.012
4/5 0.003 0.011 0.172 0.714 0.100
Table 3.4A. Assumed transition probabilities for
the four-state model.
Probabilities for time = 1
0/1
2/3
4/5
6
0.220
0.280
0.370
0.130
Conditional Transition Probabilities for time > 1
0/1
2/3
4/5
6
0/1
0.924
0.063
0.010
0.003
2/3
0.215
0.735
0.038
0.012
4/5
0.014
0.172
0.714
0.100
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Appendix 3B: assumed transition probabilities for the scenario with only one differing assumed transition
In this appendix, we present Tables 3.1B-3.4B, which show the probabilities used to determine the trajectories for the subjects
in the simulation study to approximate power when the treatment effect exists for only one transition (from mRS = 3 to mRS =
2).

Table 3.1B. Assumed transition probabilities for the seven-state model.
Probabilities for time = 1 (control)
0
1
2
3
4
5
6
0.110 (0.090) 0.130 (0.110) 0.150 (0.110) 0.110 (0.190) 0.230 (0.230) 0.140 (0.140) 0.130 (0.130)
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0
1
2
3
4
5

0
0.800 (0.800)
0.200 (0.200)
0.050 (0.050)
0.030 (0.010)
0.005 (0.005)
.0005 (.0005)

Conditional transition probabilities for time > 1 (control)
1
2
3
4
5
0.170 (0.170) 0.020 (0.020) 0.005 (0.005) 0.003 (0.003) 0.001 (0.001)
0.680 (0.680) 0.080 (0.080) 0.020 (0.020) 0.010 (0.010) 0.005 (0.005)
0.280 (0.280) 0.540 (0.540) 0.110 (0.110) 0.010 (0.010) 0.001 (0.001)
0.110 (0.050) 0.300 (0.140) 0.480 (0.720) 0.060 (0.060) 0.005 (0.005)
0.015 (0.015) 0.060 (0.060) 0.230 (0.230) 0.600 (0.600) 0.070 (0.070)
0.007 (0.007) .0075 (.0075) 0.045 (0.045) 0.280 (0.280) 0.480 (0.480)

6
0.001 (0.001)
0.005 (0.005)
0.009 (0.009)
0.015 (0.015)
0.020 (0.020)
0.180 (0.180)

Table 3.2B. Assumed transition probabilities for the six-state model.
Probabilities for time = 1 (control)
0
1
2
3
4/5
6
0.110 (0.090) 0.130 (0.110) 0.150 (0.110) 0.110 (0.190) 0.370 (0.370) 0.130 (0.130)

0
1
2
3
4/5

0
0.800 (0.800)
0.200 (0.200)
0.050 (0.050)
0.030 (0.010)
0.003 (0.003)

Conditional transition probabilities for time > 1 (control)
1
2
3
4/5
0.170 (0.170) 0.020 (0.020) 0.005 (0.005) 0.004 (0.004)
0.680 (0.680) 0.080 (0.080) 0.020 (0.020) 0.015 (0.015)
0.280 (0.280) 0.540 (0.540) 0.110 (0.110) 0.011 (0.011)
0.110 (0.050) 0.300 (0.140) 0.480 (0.720) 0.065 (0.065)
0.011 (0.011) 0.034 (0.034) 0.138 (0.138) 0.714 (0.714)

6
0.001 (0.001)
0.005 (0.005)
0.009 (0.009)
0.015 (0.015)
0.100 (0.100)
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Table 3.3B. Assumed transition probabilities for the five-state model.
Probabilities for time = 1 (control)
0
1
2/3
4/5
6
0.110 (0.090) 0.130 (0.110) 0.260 (.300) 0.370 (.370) 0.130 (0.130)
Conditional transition probabilities for time > 1 (control)
0
1
2/3
4/5
6
0 0.800 (0.800) 0.170 (0.170) 0.025 (0.025) 0.004 (0.004) 0.001 (0.001)
1 0.200 (0.200) 0.680 (0.680) 0.100 (0.100) 0.015 (0.015) 0.005 (0.005)
2/3 0.040 (0.030) 0.195 (0.165) 0.715 (0.755) 0.038 (0.038) 0.012 (0.012)
4/5 0.003 (0.003) 0.011 (0.011) 0.172 (0.172) 0.714 (0.714) 0.100 (0.100)

Table 3.4B. Assumed transition probabilities for the four-state model.
Probabilities for time = 1 (control)
0/1
2/3
4/5
6
0.120 (0.100) 0.150 (0.120) 0.230 (0.280) 0.500 (0.500)

0/1
2/3
4/5

Conditional transition probabilities for time > 1 (control)
0/1
2/3
4/5
6
0.924 (0.924) 0.063 (0.063) 0.010 (0.010) 0.003 (0.003)
0.235 (0.195) 0.715 (0.755) 0.038 (0.038) 0.012 (0.012)
0.014 (0.014) 0.172 (0.172) 0.714 (0.714) 0.100 (0.100)
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Appendix 3C: assumed transition probabilities for scenario with global treatment effect\
In this appendix, we present Tables 3.1C-3.4C, which show the probabilities used to determine the trajectories for the subjects
in the simulation study to approximate power when the treatment effect exists for all transitions.
Table 3.1C. Assumed transition probabilities for the seven-state model.
Probabilities for time = 1 (control)
0
1
2
3
4
5
6
0.150 (0.100) 0.150 (0.100) 0.140 (0.100) 0.100 (0.150) 0.200 (0.250) 0.200 (0.230) 0.050 (0.070)
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0
1
2
3
4
5

0
0.800 (0.720)
0.200 (0.160)
0.050 (0.030)
0.020 (0.010)
0.010 (0.005)
0.002 (0.001)

Conditional transition probabilities for time > 1 (control)
1
2
3
4
5
0.186 (0.230) 0.010 (0.042) 0.001 (0.002) 0.001 (0.002) 0.001 (0.002)
0.693 (0.676) 0.080 (0.120) 0.001 (0.002) 0.005 (0.010) 0.001 (0.002)
0.280 (0.220) 0.509 (0.528) 0.100 (0.140) 0.020 (0.030) 0.001 (0.002)
0.130 (0.080) 0.230 (0.200) 0.560 (0.620) 0.040 (0.050) 0.010 (0.020)
0.030 (0.020) 0.060 (0.050) 0.250 (0.200) 0.510 (0.565) 0.070 (0.080)
0.010 (0.005) 0.010 (0.005) 0.070 (0.050) 0.250 (0.200) 0.408 (0.439)

6
0.001 (0.002)
0.020 (0.030)
0.040 (0.050)
0.010 (0.020)
0.070 (0.080)
0.250 (0.300)

Table 3.2C. Assumed transition probabilities for the six-state model.
Probabilities for time = 1 (control)
0
1
2
3
4/5
0.150 (0.100) 0.150 (0.100) 0.140 (0.100) 0.100 (0.150) 0.400 (0.480)

6
0.060 (0.070)

Conditional transition probabilities for time > 1 (control)
1
2
3
4/5
0.186 (0.230) 0.010 (0.042) 0.001 (0.002) 0.002 (0.004)
0.693 (0.676) 0.080 (0.120) 0.001 (0.002) 0.006 (0.012)
0.280 (0.220) 0.509 (0.528) 0.100 (0.140) 0.021 (0.032)
0.130 (0.080) 0.230 (0.200) 0.560 (0.620) 0.050 (0.070)
0.020 (0.013) 0.035 (0.028) 0.160 (0.125) 0.619 (0.641)

6
0.001 (0.002)
0.020 (0.030)
0.040 (0.050)
0.010 (0.020)
0.160 (0.190)

0
0 0.800 (0.720)
1 0.200 (0.160)
2 0.050 (0.030)
3 0.020 (0.010)
4/5 0.006 (0.003)
66

Table 3.3C. Assumed transition probabilities for the five-state model.
Probabilities for time = 1 (control)
0
1
2/3
4/5
6
0.150 (0.100) 0.150 (0.100) 0.240 (0.250) 0.400 (0.480) 0.060 (0.070)
Conditional transition probabilities for time > 1 (control)
0
1
2/3
4/5
6
0 0.800 (0.720) 0.186 (0.230) 0.011 (0.044) 0.002 (0.004) 0.001 (0.002)
1 0.200 (0.160) 0.693 (0.676) 0.081 (0.122) 0.006 (0.012) 0.020 (0.030)
2/3 0.035 (0.020) 0.205 (0.150) 0.700 (0.745) 0.035 (0.050) 0.025 (0.035)
4/5 0.006 (0.003) 0.020 (0.013) 0.195 (0.153) 0.619 (0.641) 0.160 (0.190)

Table 3.4C. Assumed transition probabilities for the four-state model.
Probabilities for time = 1 (control)
0/1
2/3
4/5
6
0.300 (0.200) 0.240 (0.250) 0.400 (0.480) 0.060 (0.070)

0/1
2/3
4/5

Conditional transition probabilities for time > 1 (control)
0/1
2/3
4/5
6
0.939 (0.893) 0.046 (0.083) 0.004 (0.008) 0.011 (0.016)
0.240 (0.170) 0.700 (0.745) 0.035 (0.050) 0.025 (0.035)
0.026 (0.016) 0.195 (0.153) 0.619 (0.641) 0.160 (0.190)
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Appendix 3D: plots of p-values and test-statistics from type I error simulation study
In this appendix, we present Figures 3.1D and 3.2D, which display the distribution of the
p-values and test-statistics from the likelihood ratio tests from the type I error simulation
study.

Figure 3.1D. Distribution of p-values from the likelihood ratio tests calculated in the type I error simulation
study.
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Figure 3.2D. Distribution of test-statistics from the likelihood ratio tests calculated in the type I error
simulation study.
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Abstract
In clinical trials, longitudinally assessed ordinal outcomes are commonly dichotomized
and only the final measure is used for primary analysis, partly for ease of clinical
interpretation. Dichotomization of the ordinal scale and failure to utilize the repeated
measures can reduce statistical power. Additionally, in a certain emergent settings, the
same measure cannot be assessed at baseline prior to treatment. For such a data set, a
piecewise-constant multistate Markov model that incorporates a latent model for the
unobserved baseline measure is proposed. These models can be useful in analyzing
disease history data and are advantageous in clinical applications where a disease process
naturally moves through increasing stages of severity. Two examples are provided using
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acute stroke clinical trials data. Conclusions drawn in this paper are consistent with those
from the primary analysis for treatment effect in both of the motivating examples. Use of
these models allows for a more refined examination of treatment effect and describes the
movement between health states from baseline to follow-up visits which may provide
more clinical insight into the treatment effect.
Keywords
longitudinal ordinal outcome; piecewise multistate models; panel data; modified Rankin
Scale
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4.1 Introduction
Outcomes on an ordinal scale is quite common in clinical trials [78]. It is also common in
these trials to analyze the data using a dichotomized version of the ordinal measure. For
instance, in treatments of acute stroke, often the modified Rankin Scale (mRS) is used as
the primary outcome. The mRS measures functional ability using a 7-point ordinal scale
(Table 4.1). Although, mRS is measured on this 7-point scale, for testing primary
hypotheses of interest, it is commonly dichotomized either by collapsing into {0,1} vs
{2,3, 4,5, 6} or {0,1, 2} vs {3, 4,5, 6} . Loss of information, when such ordinal outcomes

are collapsed into a dichotomy, has been studied and shown to result in reduction of
statistical power [79]. In stroke trials, alternative analytic methods on the observed
ordinal scale are gaining attention [1].
Table 4.1. Modified Rankin Scale.
Score Description
0
No symptoms at all
No significant disability despite symptoms; able to carry out all usual duties and
1
activities
Slight disability; unable to carry out all previous activities but able to look after
2
own affairs without assistance
3
Moderate disability requiring some help, but able to walk without assistance
Moderately severe disability; unable to walk without assistance and unable to
4
attend to own bodily needs without assistance
Severe disability; bedridden, incontinent, and requiring constant nursing care
5
and attention
6
Dead
Another common approach in most longitudinal trials that measure mRS over
time, is to use only the final measure made at 90 days, ignoring the earlier measurements
72

because the outcome status at 90 days is considered to be the only measurement of
clinical relevance. Moreover, typically, the ultimate goal of a treatment or therapeutic
action is to achieve improvement in patient health compared to their baseline measure. To
accurately quantify improvement, a measure of the outcome at baseline would be ideal.
Conditions with sudden onset, such as traumatic brain injury, stroke and status epilepticus
often require immediate attention and treatment, posing a challenge to assess baseline
outcome measures for clinical trials that may also lack practical meaning based on patient
status. Specific to acute stroke trials the mRS is not obtainable at baseline [80]. The
current method of addressing this is to adjust for the severity of the condition (disease) at
baseline.
In this manuscript a continuous-time non-homogeneous Markov process is
proposed as an alternative to study the evolution of acute onset diseases. Of specific
interest is exploration of potential differences in transition rates between two treatment
groups. Using this method, it is possible to analyze treatment effects in the observed
ordinal scale and incorporate data measured longitudinally. In addition, after treatment,
since much of the progression or recovery experienced by acute ischemic stroke patients
is expected to occur early, on a method for predicting the baseline mRS state is proposed
[81]. This baseline mRS may then be utilized in a model that more fully characterizes the
evolution of disease over time.
The paper is organized as follows. Two motivating examples of large acute stroke
therapy trials are described in Section 4.2. Homogeneous and piecewise-constant
multistate Markov models (MSMMs) are introduced. In Section 4.3, the baseline
73

estimation procedure is described and demonstrated and piecewise-constant MSMMs
using the estimated baseline scores for the motivating examples are fit. Concluding
remarks are presented in Section 4.4.
4.2 Methods
Methods are developed and motivated through two phase III acute stroke therapy trials,
namely the National Institute of Neurologic Disorders and Stroke tissue plasminogen
activator (NINDS tPA) Stroke Study Part 2 [38] and the Albumin in Acute Stroke
(ALIAS) Trial [82].
The NINDS tPA Stroke Study Part 2 was designed to compare intravenous tPA
versus placebo in subjects with acute ischemic stroke using a global test statistic [38].
The global test statistic simultaneously tested for treatment effect in four correlated
outcomes (mRS, Barthel Index, Glasgow outcome scale and National Institutes of Health
Stroke Scale). The Barthel Index is a simple index of independence that scores the ability
of patients to care for themselves [40]. Patients that can perform all activities assessed
with complete independence are given a score of 100. The Glasgow outcome scale is a
global assessment of function that ranges from 1 indicating good recovery to 5, death
[41]. The National Institutes of Health Stroke Scale (NIHSS) is a 42-point scale that
measures neurologic deficit where 0 indicates normal function [83].
A total of 624 patients were enrolled in NINDS tPA, with 312 in each treatment
group. The primary analysis showed a significant global test score for the four
dichotomized outcomes as well as for the dichotomized mRS alone at 90 days [39]. In
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addition to the primary outcome assessment at 90 days, the mRS was collected at 7-10
days, 180 days and 360 days from randomization for each subject.
The ALIAS Trial was designed to compare 25% human serum albumin and saline
in patients with acute ischemic stroke [82]. Part 1 of the trial was suspended after
enrolling 434 subjects due to safety concerns of albumin [84]. Part 2 of the trial was
slightly redesigned with unblinded safety analysis and enrolled 841 subjects. The analysis
of both Parts 1 and 2, as well as the two combined, showed a lack of treatment effect on
primary and secondary outcomes, including the dichotomized mRS at 90 days [85]. In
addition to the primary outcome assessment at 90 days, the mRS was also collected at 30
days, 180 days, 270 days and 360 days from randomization for each subject.
4.2.1 Multistate Markov Models
MSMMs in continuous-time has been used to model the course of many diseases [4]. The
MSMMs incorporate longitudinal ordinal data and can provide clinically relevant
summary statistics to describe covariate effects, including sojourn times and transition
rates. These models are advantageous in clinical applications, where a disease process
naturally moves through increasing stages of severity [4]. Homogeneous continuous-time
MSMMs, where the transition rates are assumed to be constant over time, have been used
to analyze various diseases [86-88].
The assumption of homogeneity is not always realistic. With acute onset diseases,
the rapid nature of onset and intervention likely characterize a process that changes
quickly early on and tapers off after the initial acute recovery stage. The transition rates
of the remainder of the longitudinal disease process, after the initial burst of rapid
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movement post-baseline, are likely to differ from those observed in the acute phase. In
this case, a non-homogeneous model with piecewise constant intensity rates can be used.
Multistate Markov modeling requires that the Markov property holds for the
observed data. Consider a system with a finite state-space   {1, 2,3,..., I } , where I
represents the number of states. Let X (s  t ) be a discrete random variable that indicates
the state occupied by the system at time s  t . Let FX ( s )  { X (v) : v  s} which denotes all
information pertaining to the history of X up to time

s

[64]. The series of observations

has the Markov property if the conditional distribution of X (s  t ) given FX ( s ) , satisfies

P  X (s  t )  j | FX ( s ) , X (s)  i  P  X (s  t )  j | X (s)  i  pij (s, t ), i, j  . (4.1)
In other words, the present state depends only on the immediately preceding observation
and not on the ones before it. In the context of clinical trials, the state of the system is the
health state of one individual.
Though the ordinal outcome in acute therapy clinical trials is observed at discrete
times, the disease process is continuous, where progression or recovery can occur at any
time. Continuous-time MSMMs can analyze this type of data, known as panel data, as
long as the sampling times are considered to be noninformative [4]. In the clinical trial
setting where the observation scheme is fixed in advance, this assumption is valid. If,
however, a subject visited a clinic because of a change in symptoms and the outcome was
collected, the sampling time would be informative and could bias inference. These
continuous-time MSMMs are flexible enough to model panel data with noninformative
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sampling times but also include exact time of death, which is commonly observed in
clinical trials.
A common assumption of continuous-time MSMMs is that of homogeneity,
where transition probabilities remain constant over time. When homogeneity is assumed,
the transition probabilities, pij (t ) , are defined as
pij (t )  P{ X (s  t )  j | X (s)  i}  P{X (t )  j | X (0)  i} .

Since this expression does not depend on

s,

(4.2)

the transition from state i to state j on a

time interval of length t has the same probability at any time. The pij (t ) are elements of
the transition probability matrix, P(t ) .
The movement of a subject between states is described by ij , the transition
intensities:

ij  lim

 t 0

P( X ( t )  j | X (0)  i)
, for i  j .
t

(4.3)

The intensities represent the instantaneous rate of moving from state i to state j  i and
form the generator matrix, Λ , whose rows sum to zero and the diagonal entries are

ii   ij . The transition probability matrix P(t ) can be solved by taking a matrix
j i

exponential of Λ scaled by the time interval,


t k Λk
k 0 k !

P(t )  etΛ  

where Λ k is the kth power of the generator matrix Λ .
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(4.4)

Suppose X is observed over t0  t1  t2  ...  tM . Let i0 , i1 , i2 , ..., iM be the
observed states over these time points. Then, the associated likelihood function is
M

L( | x)  P(X 0  i0 ) P( X t j  i j | X t j1  i j 1 )
j i

M

 P(X 0  i0 ) P( X t j t j1  i j | X 0  i j 1 )

(4.5)

j i
M

 P(X 0  i0 ) Pi j1i j (t j  t j 1 ) .
j i

Using equations (4.4) in (4.5), the likelihood reduces to

  (t j  t j 1 )k ( k )i j1i j
L( | x)  Pi 0   

k!
j 1 k  0

M


,



(4.6)

where Pi 0 is the initial probability that the process is at i0 .
4.2.2 Piecewise-constant Multistate Markov Models
In the case of ischemic stroke occurrence and treatment, subjects can get better or worse
very quickly. For this reason, the time homogeneity assumption is expected to fail for the
first transition, from the estimated baseline to the first observed outcome. Therefore,
assumption of homogeneity is relaxed and a non-homogeneous model is considered.
The MSMM for panel data can be extended to accommodate piecewise-constant
intensity matrices for the non-homogeneous case [59]. Here, the transition probability
functions are dependent on

s

and the transition matrix function is P(s, t )  ( pij (s, t )) . The

transition intensity functions are now defined by
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P( X (t   t )  j | X (t)  i )
, i, j  S , i  j .
 t 0
t

ij (t )  lim

(4.7)

The time-homogeneity assumption can be tested by using a likelihood ratio test to
compare the time-homogenous model to piecewise-constant models with different cutoff
times.
The effect of a covariate, specifically treatment, is incorporated into the model as
transition intensity functions [69]. Let z be a vector of observed covariates then
ij (t; z )  ij (t ) exp( z ' ij (t )), ij (t )  0

(4.8)

where ij (t ) is the parameter vector associated with the covariate vector z in the
transition between states i and j in time t . The transitional rates are represented by
ij (t; z ) at time t for the subjects with vector z .

4.2.3 Latent Baseline Estimation
To consider the full evolution of ischemic stroke over time, an estimated baseline
functional outcome is needed because baseline mRS is not obtainable in the acute setting.
While functional outcome is not available at baseline, many other measures that are
correlated with functionality are available. An estimation procedure using baseline
characteristics known to be highly correlated with the mRS was developed.
As a preliminary step, to summarize information from numerous baseline
measurements considered clinically relevant for functional outcome in ischemic stroke
patients, data reduction was performed using a Principal Components Analysis (PCA).
The items included in the PCA were age, baseline glucose, time from stroke onset to
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randomization, the Alberta Stroke Program Early CT score (ASPECTS), and NIHSS.
Age and time from stroke onset to randomization are two very well established predictors
of outcome in acute stroke. Another baseline characteristic associated with poor outcome
is “stress” hyperglycemia [89]. This hyperglycemia can be quantified using acute poststroke glucose levels. The ASPECTS is also a strong prognostic indicator of outcome
[90], which is a 10-point quantitative topographic CT scan score, where a normal scan
receives a score of 10 [91]. For each defined region of the brain, a point is subtracted if
there is evidence of ischemic change. The NIHSS is commonly used to measure baseline
stroke severity. The individual items of the scale are presented in Appendix 4A. Baseline
NIHSS is known to strongly predict outcome in acute stroke therapy trials [92]. Although
total score is typically used for indicating stroke severity, each item of the scale was used
in the PCA individually in order to more efficiently assess the contribution of each facet
of the scale.
After reducing the data to fewer PCA’s sextiles (six categories because the
seventh category, namely mRS = 6 corresponds to death) based on the joint distributions
of the PCA’s will be used to define the baseline states of the individuals. Then the
MSMM likelihood ratio tests will be used to compare treatment effects. However, in this
likelihood ratio test, the uncertainty of the estimated baseline states has to be considered.
This is achieved through bootstrap approach, using which an empirical distribution was
derived to determine the p-values. The steps used in this non-parametric bootstrap
approach are as follows:
1. Sample with replacement from the original dataset 1,000 times.
80

2. Use the baseline estimation procedure from the original data on each of the 1,000
bootstrapped samples (fixing the number of significant components as well as the
variables used in each of the component score calculation).
3. Fit the piecewise MSMM to each resample and obtain the test statistic.
4. Compare the original test statistic to the new bootstrap distribution, made up of
the 1,000 test statistics from the bootstrap samples.
5. The bootstrap p-value is calculated by finding the proportion of bootstrap samples
in which the test statistics is larger than or equal to the one calculated from the
original sample.
4.3 Results
Detailed descriptions of the PCA for each trial are presented in Appendix 4B. For both
NINDS tPA and ALIAS, most of the variability was adequately explained by the first two
components. Thus, component scores were calculated for Components 1 and 2 for each
trial. Larger values on the component scores were expected to be associated with worse
functional outcome. To assign the baseline mRS state, each of the component scores were
divided into sextiles with equal probability. In Figure 4.1, the joint distribution of the two
discretized scores are shown were used to assign values of mRS = 0 to mRS = 5 with
equal probability (subjects cannot be dead at baseline, so no one was assigned an mRS =
6). There is uncertainty in the assignment of baseline states which needs to be accounted
for in the hypothesis tests comparing treatments.
In the NINDS tPA trial, several subjects either did not have available CT scans or
the scans were not of sufficient quality to obtain ASPECTS (16/624). Scores for the
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second component could not be calculated and subsequently the baseline mRS could not
be estimated. These subjects were not excluded from the analysis unless they died in the
first week of follow-up, leaving them with only one observed mRS score (5/624).
Therefore, the total number of subjects included in the MSMM was 619, where 320 were
randomized to receive tPA and 323 to receive placebo.

Figure 4.1: Baseline mRS score from summed standardized component scores for: (a) NINDS tPA and (b)
ALIAS.

4.3.1 The Longitudinal Data
In the ALIAS Trial, a small number of subjects withdrew consent or were lost-to
follow-up prior to the 30 day visit and had only one observation available, the estimated
baseline mRS (17/1275). Excluding these subjects, a total of 1258 were included in the
MSMM, where 628 were randomized to receive albumin and 630 to receive placebo. In
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Appendix 4C, baseline characteristics of the 17 excluded subjects are summarized
alongside those of the subjects that were not excluded. No notable differences exist
between the groups and thus the exclusion of these subjects should be inconsequential in
the analysis.
4.3.2 Development of MSMM for the NINDS tPA Study and ALIAS
In order to analyze panel data with continuous-time Markov chains it is important to
consider which transitions can realistically occur in continuous time. When states
represent severity it is assumed that in order for a subject to transition from one state to
another non-adjacent state they also transition through the intermediate states. Thus, a
reduced transition intensity matrix should be estimated, where non-adjacent state
transitions are fixed to equal zero. The exception is when a state represents death. The
reality is that a subject can die from any state.
In practice, if there is not enough information from the data, on a certain transition
rate, more transition intensities may need to be set to zero [4]. State tables display counts
of the pairs of transitions between states in successive observation times and summarize
them in frequency tables of previous state against current state. These state tables can be
used to identify counts that are too few to model.
The state table of all aggregate transtions from the NINDS tPA data (baseline to
360 days) is displayed in Table 4.2. Even though it is possible for subjects to die from
any state, it is highly unlikely to occur from states 1, 2, 3 or 4. This is not surprising as
subjects are only observed over the course of one year. The relatively healthy subjects
have a low risk of death. Therefore more constraints are required for this model. When
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the table is stratified by time for the piecewise model and again by treatment, the
frequency of death from the healthier states (1, 2, 3 and 4) is too small to estimate the
transition intensities. As a result, the original model was modified to no longer allow
death from any state. Constraints were imposed such that death was only allowable from
states 5 and 6.
Table 4.2. NINDS tPA state table.
To (state j)
1
2
3
4
5
From (state i)
1
206 52 9
3
5
2
87 245 39 12 23
3
23 73 85 35 32
4
13 41 62 148 52
5
11 26 27 84 187
6
4
8
7
25 83
Total
344 445 229 307 382

6

7

Total

0
7
14
25
53
142
241

2
8
10
10
41
83
154

277
421
272
351
429
352
2102

Similarly, when the state table was examined for ALIAS, small counts were
observed for death from states 1, 2 and 3. The reduced allowable transition matrix for
ALIAS fixed the intensities from these states to death to equal 0, only allowing the
intensities from 4, 5 and 6 to death to be estimated.
4.3.3 Analysis of the NINDS tPA Study and ALIAS
The entries of the transition intensity matrices were estimated by applying the maximumlikelihood method and accounting for the two constant intervals partitioned at time
t  .333 (representative of 7-10 days on a month-long interval) in the NINDS tPA trial

and time t  1 (representative of 30 days) in ALIAS. Analysis was performed using the
msm package in R using the Broyden-Fletcher-Goldfarb-Shanno method [4].
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For the NINDS tPA trial, using a likelihood ratio test to compare the piecewise
model including treatment (-2LL = 6251) to one without treatment (-2LL = 6282), the
model with treatment was preferred, indicating a statistically significant treatment effect
on the transition rates (p = 0.002, df = 12). It is interesting to note that in models
excluding estimated baseline mRS, the comparison of a model with treatment (-2LL =
4033) adjusting for baseline NIHSS to one without treatment (-2LL = 4053) failed to
detect a statistically significant treatment effect (p = 0.053, df = 12).
In ALIAS, using a likelihood ratio test to compare the piecewise model including
treatment (-2LL = 12730) to one without (-2LL = 12745), the reduced model was
preferred, indicating no significant treatment effect on the transition rates (p = 0.29, df =
13), confirming the results from the primary analysis of the trial [43].
For NINDS tPA, after comparing the empirical distribution to the observed test
statistic of 31.18, the p-value from the bootstrap procedure was 0.04 which is larger than
the observed p-value of 0.002 but still indicative of a significant treatment effect. For
ALIAS, the p-value calculated from the bootstrap procedure, where the test statistic from
the analysis of the original sample was 15.25, was 0.49 which is also larger than the
observed p-value of 0.29 but results in the same conclusion that there is no a significant
treatment effect.
Table 4.3 shows the transition intensities estimated in the piecewise-constant
model for the NINDS tPA Stroke Study. Transition rates differ between the placebo and
tPA groups. The differences between groups can also be presented using hazard ratios
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(Table 4.4). A hazard ratio greater than one indicates that the rate of transition is higher in
the treatment group.
The only statistically significant hazard ratio was from state 2 to state 3 (HR =
0.51). This can be interpreted as the most significant impact of tPA is to reduce the
hazard of transitioning from mRS = 1 to mRS = 2. The other hazard ratios, although not
statistically significant, suggest a trend of tPA reducing the hazard of negative transitions.
Table 4.3. Maximum-likelihood estimates of transition rates among states.
Placebo
tPA
Transition
0 ≤ t ≤ 0.333
t > 0.333
0 ≤ t ≤ 0.333
t > 0.333
10.83 (2.36, 49.71) 0.09 (0.06, 0.14) 7.91 (1.89, 33.06) 0.07 (0.05, 0.09)
12
19.30 (6.07, 61.37) 0.09 (0.06, 0.15) 9.75 (3.15, 30.22) 0.05 (0.03, 0.07)
23
12.84 (6.53, 25.28) 0.19 (0.12, 0.32) 16.59 (7.09, 38.86) 0.25 (0.14, 0.44)
34
24.03 (10.50, 54.98) 0.12 (0.08, 0.19) 16.07 (6.71, 38.50) 0.08 (0.05, 0.13)
45
2.97 (1.92, 4.59)
0.05 (0.04, 0.10) 2.63 (1.70, 4.07)
0.05 (0.03, 0.09)
56
0.48 (0.27, 0.86)
0.05 (0.04, 0.07) 0.46 (0.26, 0.83)
0.05 (0.03, 0.07)
57
0.50 (0.28, 0.88)
0.12 (0.09, 0.18) 0.60 (0.35, 1.02)
0.15 (0.10, 0.21)
67
7.53 (1.64, 34.55)
0.08 (0.05, 0.11) 7.54 (1.85, 30.72) 0.08 (0.06, 0.10)
21
18.06 (5.49, 59.44) 0.23 (0.16, 0.32) 20.59 (6.43, 65.91) 0.26 (0.18, 0.36)
32
14.15 (6.74, 29.71) 0.22 (0.15, 0.32) 14.06 (6.09, 32.46) 0.22 (0.15, 0.33)
43
6.29 (2.59, 15.26)
0.20 (0.15, 0.27) 6.86 (2.86, 16.46) 0.22 (0.16, 0.30)
54
3.08 (2.01, 4.72)
0.23 (0.17, 0.32) 2.46 (1.61, 3.77)
0.18 (0.13, 0.26)
65
Table 4.4. Hazard ratios (95% CI).
12
0.73 (0.43, 1.23)
23
0.51 (0.28, 0.90)
34
1.29 (0.66, 2.52)
45
0.67 (0.38, 1.17)
56
0.88 (0.53, 1.48)
57
0.96 (0.55, 1.66)
67
1.20 (0.75, 1.92)
21
1.00 (0.62, 1.62)
32
1.14 (0.71, 1.83)
43
0.99 (0.59, 1.68)
54
1.09 (0.72, 1.65)
65
0.80 (0.52, 1.23)
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4.4 Summary and Discussion
Dichotomization of ordinal outcomes is common but results in a loss of information and
can reduce statistical power. Some patients with severe disability at baseline may never
have the potential to achieve success as defined by the dichotomy. Thus, the prognostic
heterogeneity of subjects does not allow for potential equal contribution to the estimation
of treatment effect for all subjects with a dichotomized outcome [9].
A number of alternative methods for ordinal outcome data have received attention
in recent years [93]. Linear regression and analysis of variance have been suggested
where the ordinal outcome is treated as a continuous variable. Summary statistics from
these models do not have straightforward interpretations because non-integer values from
ordinal scales do not have a clear meaning.
A number of ordinal analyses have also been suggested. Ordinal logistic
regression, under the assumption of proportional odds, assumes an identical effect of the
predictors for each cumulative probability [45]. If the proportional odds assumption
holds, statistical power can be increased as compared to analysis using a strict dichotomy.
The score test for assessing the proportional odds assumption, however, is
anticonservative. If the assumption fails, this analysis could mask important effects at one
end of the ordinal outcome [46]. The partial proportional odds model relaxes this
assumption and includes a term that allows the odds ratios to increase proportional to the
outcome scale [46]. Alternatively, the cumulative logit model allows for the calculation
of odds ratios for each adjacent category of response in relation to covariates and does
not require the proportional odds assumption [45]. One drawback of both the partial
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proportional odds and cumulative logit models is that they can require a larger sample
size to be adequately powered.
The sliding dichotomy is another alternative method for the analysis of ordinal
outcomes. It allows for the definition of success to vary based on patient-specific baseline
prognostic variables while maintaining a dichotomized outcome, however, there are no
guidelines for selection of number of prognostic groups nor cut points for those groups
[48]. Poor selection of these groups could lead to a reduction in power. Furthermore,
while the sliding dichotomy allows for baseline severity adjusted outcome, it still ignores
any non-successful transitions [94].
The Cochran-Mantel Haenszel (CMH) shift test can also be used to analyze the
distribution of ordinal data [7]. This test can show whether a treatment causes a
significant shift toward good outcome. Shift analysis can account for ordered categories,
has no distributional assumptions and is easy to implement. However, it is not feasible for
large scale clinical trials with non-simple randomization schemes because it can only
accommodate a limited number of covariates. There are also no summary statistics that
appeal to a clinical audience so proportional odds logistic regression is often used in
conjunction with the CMH test to provide an estimate of treatment effect [44]. In
addition, shift analysis assumes that a treatment effect exists only in one direction, where
only benefit is considered, not harm.
An approach to transform the mRS into a patient-centered outcome measure was
recently proposed [53]. The chosen patient-centered outcome measure was utility, which
is the desirability of a specific health outcome to a patient [54]. The utility weights were
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derived for each level of the mRS by averaging utility values derived in two studies,
using two different methods. Analysis using the utility weights is straightforward as the
weights have already been defined and the utility-weighted mRS is analyzed using a t
test. Though this method is easy to implement and provides greater statistical power, it is
based on only two populations and may not be representative of patients in other
locations. In addition, the utility values do not have as clear of an interpretation as some
other analysis methods.
None of the previously mentioned methods utilize the repeated measures even
though outcome is collected over time. In fact, a literature search for repeated measures
analysis of acute stroke trial data only returned one article where a generalized estimating
equations approach was used for repeated measures analysis [11]. This approach only
considered the dichotomized outcomes from the NINDS tPA study. The work presented
here is the first known study of the repeated measures acute stroke therapy data using the
ordinal scale.
The results presented in this manuscript are the first to estimate a missing baseline
ordinal outcome for use in a MSMM. In the case of ischemic stroke occurrence and
treatment much of the progression or recovery experienced by a patient is expected to
occur early. Functional outcome measures are not suitable at baseline and as a result,
functional changes over time from baseline cannot be measured. Therefore, latent
estimation the functional baseline was warranted, allowing for inclusion of an
informative transition from baseline to first follow-up to be included in a longitudinal
model.
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Using the longitudinal data, including the estimated baseline, this work showed
that there are differences in the rate of transitions between the treatment and placebo
groups in the NINDS tPA trial, confirming the results of the primary analysis while
allowing for examination of the effect on all adjacent-state transitions. The ability to
estimate the intensities for all adjacent-state transitions allowed for examination of the
most significant effect of treatment. Specifically, it was determined that the most
significant impact of tPA is reduction the hazard of transitioning from mRS = 1 to mRS =
2. In addition, the conclusion of no treatment effect in the ALIAS Trial data was also
consistent with the primary analysis from that trial.
In the MSMM of the NINDS tPA data, where the estimated baseline was not
included and the model adjusted for baseline NIHSS instead, as is done in most other
types of analysis of the mRS, the effect of treatment was only marginally significant.
Thus, it seems as though inclusion of the estimated baseline mRS improved the ability to
detect a treatment effect. It is hypothesized that the inclusion of the latently estimated
baseline mRS is improves the model because of the acute nature of ischemic stroke
therapy and the expected early recovery and disease progression directly following
treatment.
The MSMM can incorporate longitudinal ordinal data and provide clinically
interpretable summary statistics to describe covariate effects on all transition rates and
sojourn times. Estimation of transition rates can describe treatment effect in a much finer
gradient than modeling collapsed ordinal scale allowing for a more comprehensive
understanding of differences in the effect of treatment. The MSMM also allows for
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specific hypotheses to be tested-- for example a likelihood ratio test could be used to test
whether the effect of treatment is the same for all forward transitions and backward
transitions [59].
Another benefit of these models is the potentially decreased sample size needed to
detect a treatment effect. A previous simulation study indicated that the power of
MSMMs applied to acute onset clinical trial data was significantly increased when the
number of follow-up visits was increased [93]. Future trials could collect the ordinal
outcome more frequently over the course of follow-up, increasing the power to detect
differences using this modeling technique.
A limitation of MSMMs is that they are computationally intensive, especially
when using bootstrapping to obtain the bootstrap empirical distribution. In addition, use
of these models requires a priori decisions about the transitions that can realistically
occur, which may be a data driven decision. Interpretation of the full model could
potentially be overwhelming, as there are many parameters that describe the effect of one
covariate; however, the model also allows for testing whether the effect of a covariate is
the same for certain transitions, which could reduce the number of parameters. The
flexibility to estimate the full or reduced model allows a number of clinical questions to
be answered using one approach.
Future directions could include more complex methods for baseline estimation.
For example, a Bayesian PCA could be used in alternative baseline estimation procedure.
This method could potentially address the uncertainty of the assigned baseline scores via
extraction of the posterior distributions for the component scores [95]. In addition, the
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methods presented for estimation could be extended to cases where more than two
components were used in the estimation procedure.
Acknowledgements
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4.5 Appendices
Appendix 4A: modified NIHSS summary
In this appendix, Table 4.1A is presented, which shows the 15 items of the NIHSS. The
form for recording the data contains detailed instructions for use of the scale.

93

Table 4.1A. The Modified National Institutes of Health Stroke Scale
Summary.
1A Level of Consciousness
0 = Alert
1 = Not alert, obtunded
3 = Unresponsive
1B LOC Questions
0 = Answers both correctly
1 = Answers one correctly
2 = Answers neither correctly
1C LOC Commands
0 = Performs both tasks correctly
1 = Performs one task correctly
2 = Performs neither task
2
Best Gaze
0 = Normal
1 = Partial gaze palsy
2 = Total gaze palsy
3
Visual
0 = No visual loss
1 = Partial hemianopia
2 = Complete hemianopia
3 = Bilateral hemianopia
4
Facial Palsy
0 = Normal
1 = Minor paralysis
2 = Partial paralysis
3 = Complete paralysis
5
Motor Arm
0 = No drift
a. Left
1 = Drift before 10 seconds
b. Right
2 = Falls before 10 seconds
3 = No effort against gravity
4 = No movement
6
Motor Leg
0 = No drift
c. Left
1 = Drift before 10 seconds
d. Right
2 = Falls before 10 seconds
3 = No effort against gravity
4 = No movement
7
Limb Ataxia
0 = Absent
1 = Present in one limb
2 = Present in two limbs
8
Sensory
0 = Normal
1 = Mild to moderate sensory loss
2 = Severe to total sensory loss
9
Best Language
0 = No aphasia, normal
1 = Mild to moderate aphasia
2 = Severe aphasia
3 = Mute or global aphasia
10 Dysarthria
0 = Normal
1 = Mild to moderate
2 = Severe
11 Extinction and Inattention (Neglect) 0 = No abnormality
1 = Mild
2 = Severe
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Appendix 4B: data reduction using principal component analysis
When applied to a set of variables, PCA can group correlated variables into a smaller set
of composite variables (principal components). The resulting linear combinations of
variables account for as much variability in the data as possible and can be used to
calculate component scores. A number of methods exist for computation of component
scores. Non-refined methods are simple, easy to compute and easy to interpret, while
refined methods are more complex and exact [96]. Refined computation methods are
generally less stable across samples; hence, a non-refined method is implemented for the
motivating data sets. Of the non-refined methods, the summation of standardized
variables is preferred when the standard deviations of the raw data vary widely, as was
found in the NINDS tPA and ALIAS data.
PCA was used to group measures of severity (individual items of the NIHSS) and
other baseline variables known to be associated with functional ability (age, baseline
glucose, time from stroke onset to randomization and ASPECTS score) into components
and calculate component scores. For the analysis using PCA, variables were reformatted
so that the direction of effect was consistent across all candidate variable and
standardized scales were used. Component scores from PCA are more intuitive if the
expected relationship with the variables and outcome is in the same direction. For
example, increased age increases the risk of a negative outcome. All of the variables
included in the PCA are positively correlated with bad outcome except ASPECTS. A
smaller ASPECTS is predictive of negative outcome. For interpretation, the direction of
the ASPECTS scale was reformatted such that 10 represented the worst and 0 normal.
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Figure 4.1B. Scree plot of eigenvalues from PCA of baseline variables from: (a) NINDS tPA and (b)
ALIAS.

In the process of determining the number of components to retain from the PCA
analysis, the eigenvalues of the correlation matrix were visually assessed using scree
plots (Figure 4.1B). From this illustration it can be seen that the line flattens after the
second component in the scree plot for both NINDS tPA (a) and ALIAS (b) and thus the
first two components were found to adequately explain most of the variability. In order to
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assess how strongly the components and variables are related, the component loadings for
retained components were examined. Component loadings can be interpreted as the
correlation between an observed variable and a component. A general rule of thumb
deems components with loadings of at least |.4| highly explanatory [97].
The loadings for the first two components are displayed in Table 4.1B. Based on
the criteria outlined above, baseline glucose, time from onset to randomization, and
individual NIHSS items Q1A and Q07 were not included in the component score
calculation for NINDS tPA. Age, baseline glucose, time from onset to randomization, and
individual NIHSS items Q07 and Q10 were not included in the component score
calculation for ALIAS.
Table 4.1B. Factor loadings on components based on PCA.
NINDS tPA
ALIAS
Components Components
1
2
1
2
Age
0.15 -0.03 0.16 0.13
Baseline glucose
0.10 -0.04 0.06 -0.02
Stroke onset to randomization
-0.08 -0.06 0.03 -0.04
NIHSS item
Q1A – Level of Consciousness (LOC) 0.38 0.39 0.32 0.42
Q1B – LOC Questions
0.78 -0.18 0.80 -0.01
Q1C – LOC Commands
0.75 -0.01 0.78 0.14
Q02 – Best Gaze
0.37 0.66 0.20 0.71
Q03 – Visual
0.36 0.61 0.25 0.64
Q04 – Facial Palsy
0.22 0.50 0.01 0.48
Q5A – Motor Arm Left
-0.39 0.77 -0.63 0.58
Q5B – Motor Arm Right
0.84 -0.20 0.82 -0.01
Q6A – Motor Leg Left
-0.25 0.74 -0.53 0.56
Q6B – Motor Leg Right
0.80 -0.11 0.76 0.03
Q07 – Limb Ataxia
-0.20 -0.21 -0.15 -0.24
Q08 – Sensory
0.20 0.60 -0.02 0.54
Q09 – Best Language
0.86 -0.19 0.87 -0.03
Q10 – Dysarthria
0.60 0.04 0.35 0.22
Q11 – Extinction and Inattention
0.15 0.70 -0.09 0.68
ASPECTS
0.15 0.49 0.15 0.48
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Each of the variables deemed important with the cutoff of >|.4| on the first two
components were standardized to range [0, 1]. The standardized values of variables that
loaded high on each component were summed to calculate the component scores as
follows:


NINDS tPA Component Score 1 =
Q1B + Q1C + Q5B + Q6B + Q09 + Q10



NINDS tPA Component Score 2 =
Q02 + Q03 + Q04 + Q5A + Q6A + Q08 + Q11 + ASPECTS



ALIAS Component Score 1 =
Q1B + Q1C + Q5B + Q6B + Q09



ALIAS Component Score 2 =
Q1A + Q02 + Q03 + Q04 + Q5A + Q6A + Q08 + Q11 + ASPECTS.

These component scores were then used in the main manuscript to assign baseline mRS
state.
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Appendix 4C: baseline characteristics of ALIAS subjects included and excluded
from MSMM analysis
In this appendix, Table 4.1C is presented with baseline characteristics of the 17 ALIAS
subjects excluded from the analysis because of withdrawn consent or lost-to-follow-up
prior to the 30 day visit in combination with all mRS scores missing post-baseline.
Table 4.1C. Baseline Characteristics of the Subjects.
Characteristic

Included
(N = 1258)
66.1 (13.6)
674 (53.6)

Excluded
(N = 17)
62.6 (15.3)
10 (58.8)

White
Black
Asian
American Indian/Alaska Native/First
Nations People
Native Hawaiian or Pacific islander
Multiple, Other, or Unknown

969 (77.0)
197 (15.7)
60 (4.8)
7 (0.6)

13 (76.5)
3 (17.7)
0 (0.0)
0 (0.0)

3 (0.2)
1 (0.1)

0 (0.0)
0 (0.0)

Non-Hispanic/Latino
Hispanic/Latino
Unknown

1147 (91.2)
60 (4.8)
51 (4.1)

15 (88.2)
2 (11.8)
0 (0.0)

Hypertension
Atrial fibrillation
Past congestive heart failure
Past myocardial infarction
Past stroke
Past transient ischaemic attack
Diabetes mellitus
Hyperlipidemia
Peripheral vascular disease

911 (72.4)
257 (20.4)
55 (4.4)
155 (12.3)
238 (18.9)
157 (12.5)
261 (20.8)
554 (44.0)
75 (6.0)

10 (58.8)
2 (11.8)
1 (5.9)
5 (29.4)
6 (35.3)
2 (11.8)
4 (23.5)
8 (47.1)
1 (5.9)

11 (8 - 17)
932/1238 (75.3)

9 (7 – 13)
15/16 (93.8)

156.9 (29.0)
7.4 (3.2)
90.2 (25.9)

157.3 (31.3)
7.9 (3.3)
92.7 (27.4)

Age [mean (SD)]
Male sex [n (%)]

Race
[n (%)]

Ethnic
group
[n (%)]

Medical
history
[n (%)]

Baseline NIHSS score [median, (inter-quartile range)]
Baseline
Baseline ASPECTS > 7 [n/N, (%)]
ASPECTS
score
Clinical
findings
[mean (SD)]

Systolic blood pressure, mm Hg
Plasma glucose, mmol/L
Creatinine, µmol/L
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Abstract
Background and Purpose – Historically, ordinal measures of functional outcome have
been dichotomized for the primary analysis in trials of acute stroke therapy. A number of
alternative methods to analyze the ordinal scales have been proposed, with an emphasis
on maintaining the ordinal structure as much as possible. In addition, despite the
availability of longitudinal outcome data in many trials, the primary analysis consists of a
single endpoint. Inclusion of information about the course of disease progression allows
for a more complete understanding of the treatment effect.
Methods – Multistate Markov modeling, which allows for the full ordinal scale to be
analyzed longitudinally, is compared with previously suggested analytic techniques for
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the ordinal modified Rankin Scale (dichotomous-logistic regression; continuous-linear
regression; ordinal- shift analysis, proportional odds model, partial proportional odds
model, adjacent categories logit model; sliding dichotomy; utility weights; repeated
measures). Each of the methods is used to re-analyze the National Institute of
Neurological Diseases and Stroke tissue plasminogen activator study.
Results – All methods detected a statistically significant treatment effect except the
multistate Markov model without predicted baseline (p=0.053). The multistate Markov
model allows for a more refined examination of treatment effect and describes the
movement between modified Rankin Scale states over time which may provide more
clinical insight into the treatment effect.
Conclusions – Multistate Markov models are feasible and desirable in describing
treatment effect in acute stroke therapy trials. Future trials could increase power to detect
a treatment effect using these models by collecting the outcome more frequently.
Keywords
acute stroke; outcomes; randomized controlled trials; statistical analysis

101

5.1 Introduction
A number of potential explanations for the failure of most acute stroke therapy trials to
show efficacy have been discussed, including differences in preclinical and clinical
models, inappropriate inclusion criteria, and poor methodological and statistical standards
[6]. Specifically, there has been a recent emphasis on exploring alternative outcomes and
analytic methods for stroke therapy trials.
The modified Rankin Scale (mRS) is the most commonly chosen primary
outcome measure in clinical trials of acute stroke therapy [2]. Despite the ordinality of
the outcome measure, many trials have dichotomized the mRS for the primary analysis
[7]. In general, ignoring these differences and dichotomizing does not allow for
examination of the treatment effect at finer gradients of the scale and can result in a loss
of statistical power [1]. Any reduction in power may result in failure to find a clinically
meaningful treatment effect during analysis of the data. The mRS should be analyzed in
such a way that maintains the original structure of the scale as much as possible, using
continuous or ordinal approaches [1, 3].
A number of alternative methods have been proposed to improve the analysis of
the mRS. Some trials have analyzed the mRS as a continuous outcome, utilizing t-tests or
linear regression [71]. Other trials have used the Cochran-Mantel Haenszel (CMH) shift
test to analyze the distribution of the mRS, where the primary outcome is a favorable
shift toward better functional outcome [7]. Ordinal logistic regression has also been
proposed and applied in re-analysis of stroke trial data [46]. The proportional odds model
(POM) has been used but the test for the proportional odds assumption is not well102

powered. In cases where the assumption was not justifiable, the partial proportion odds
model (PPOM) or the adjacent categories logit (ACAT) has been used [46]. A popular
alternative to continuous, ordinal and strict dichotomous analysis is responder analysis or
the sliding dichotomy, where the definition of success is allowed to vary depending on
baseline severity [48]. Most recently, a utility weighted mRS (UW-mRS) was derived to
provide a patient centered metric of the degree of benefit or harm of a treatment that can
be analyzed with a t-test or linear regression [53, 98].
A drawback of the outcome measures and analytic strategies listed above is that
each analyzes data from a single endpoint, commonly the 90 day outcome, for the
primary analysis despite the availability of repeated response measures collected over the
course of longitudinal follow-up. Inclusion of information about the course of disease
progression, using the longitudinal data, allows for a more comprehensive understanding
of the benefit of a treatment [99]. None of the previously mentioned methods have
utilized the repeated measures data. A literature search for repeated measures analysis of
acute stroke trial data returned only two articles where a generalized estimating equations
approach was used for repeated measures analysis of the mRS [11, 58].
Most recently, the Multistate Markov model (MSMM) was proposed for analysis
of the mRS [93, 100]. The MSMM analyzes repeated measures data with ordinal
outcomes. These types of models describe how a subject moves between a series of
disease states over time, which is desirable in the description of disease processes that
naturally move through increasing stages of severity [59]. Results suggest that the
MSMM can be a more efficient approach than dichotomized methods used to analyze the
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mRS data in some scenarios [93]. MSMMs can provide a better clinical understanding of
the disease process since the information from the entire course of the disease is used to
estimate the parameters of the model.
The purpose of this article is to demonstrate the MSMM as an approach for
analysis of the mRS. The MSMM and the alternative methods listed above will be used to
re-analyze the National Institute of Neurological Disorders and Stroke (NINDS) tissue
plasminogen activator (t-PA) trial data. The results from each of the analytical analysis
approaches will be compared with the results using the MSMM approach.
5.2 Materials and Methods
5.2.1 Trial Data
The seminal NINDS t-PA trial showed a consistently significant effect of t-PA using a
global test of four outcomes (Barthel Index, mRS, Glasgow Outcome Scale and NIHSS)
in the analysis of the primary outcome at 90 days post-stroke [39]. In addition to the 90
day primary outcome assessment, the mRS was also collected at 7-10 days, 180 days and
360 days from randomization.
Acute stroke requires immediate attention and treatment, posing a challenge to
assess baseline outcome measures for clinical trials. Thus, the mRS is not obtainable at
baseline and most often analysis is adjusted for baseline severity using the NIHSS [80].
Much of the progression or recovery experienced by a patient suffering from an acute
onset disease is expected to occur early on. Moreover, typically, the goal of a treatment or
therapeutic action is improvement in patient health compared to their baseline measure.
To accurately quantify improvement, a measure of the outcome at baseline is ideal.
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A prediction procedure using principal component analysis (PCA) for data
reduction of baseline variables known to be correlated with functional ability was
previously described [100]. Briefly, PCA is a statistical data reduction method that, when
applied to a large set of variables, can group correlated variables into a smaller set of
important composite variables, or components. The PCA grouped measures of severity
(individual items of the NIHSS) and other baseline variables known to be associated with
functional ability (age, baseline glucose, time from stroke onset to randomization and the
Alberta Stroke Program Early CT score) into components to calculate component scores.
The resulting component scores were used to assign the latent baseline mRS score and
thus creating a comparable baseline mRS for analysis purposes.
5.2.2 Multistate Markov Models
In this paper, continuous-time MSMMs are used to describe the progression and recovery
between mRS levels, or the disease states, over time. The main assumption of the
MSMM is that the probabilities governing the transition between states only depend on
the current state occupied by an individual, and not on previous disease history.
Death (mRS = 6) is known as an absorbing state because transitions out of this
state cannot occur and mRS scores of 0 to 5 are examples of transient states, where
transitions are allowed between the states. The data from the NINDS t-PA trial were
observed at arbitrary times that were specified in advance so exact times of state
transitions are unknown. Data of this type, observations of a continuous process at
discrete times, are called panel data. Because the underlying disease process is
continuous, where progression or recovery can happen at any time, it is assumed that in
105

order for a subject to transition from one state to a non-adjacent state they also transition
through the intermediate states [4]. Thus, the general MSMM for panel data only
estimates adjacent state transitions and transitions to death from any state. The allowable
transitions between transient and absorbing states for the general model of the mRS are
illustrated in Figure 5.1, where arrows indicate the allowed transitions between states.
MSMMs of panel data are governed by transition intensities that depend on time
and individual level or time-dependent covariates. The transition intensities represent the
instantaneous risk of transition between two mRS scores. Commonly, the transition
intensities are assumed to be constant over time but this is often an unrealistic
assumption. If the assumption fails, a model with piecewise-constant transition intensities
can be used. This allows for the transition intensity matrices to change at breakpoints,
remaining constant between the breakpoints. In addition to transition intensities,
transition probabilities can also be estimated based on the observed transition rates using
maximum likelihood estimation [4]. When modeling covariates in a MSMM, hazard
ratios can be estimated that correspond to the effect of a covariate on the transition
intensities.

Figure 5.1. General MSMM for panel observed mRS data.
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Likelihood ratio test (LRT) statistics are used to compare nested MSMMs. A
reduced model is nested in a more complex model if all of the terms in the smaller model
occur in the larger model. If two nested models are compared and the test is significant,
then the more complex model fits the data better than the reduced model. LRTs are used
to determine the significance of covariates and to compare models with constant
transition intensities to ones with piecewise-constant intensities.
5.2.3 Statistical Analysis and Assumptions
For analyses using a fixed dichotomy, favorable outcome was defined as mRS ≤ 1, as
was done in the primary paper [38]. The PPOM includes an additional term using a
second parameter that allows for the ORs to increase proportional to the outcome scale.
This PPOM, the restricted PPOM, is used when there is a linear deviation from the
proportional odds assumption required for the POM, which is true of the NINDS t-PA
data [46]. For the sliding dichotomy analysis, favorable outcome was defined to be
consistent with previous re-analysis of the NINDS t-PA data where mRS = 0 for subjects
with mild stroke (NIHSS < 7), mRS ≤ 1 for subjects with moderate stroke (NIHSS = 814) and mRS ≤ 2 (NIHSS > 14) [101]. The UW-mRS values were derived by averaging
patient centered and person-tradeoff studies and are reported by Chaisinanunkul et al
[53].
The ACAT and MSMMs were fit in R statistical software version 3.3.0 using the
VGAM and msm packages, respectively. All other analysis was completed in SAS 9.4.
When appropriate, analyses were adjusted for baseline NIHSS, which is known to be
highly predictive of outcome [92]. The model using responder analysis as well as the
107

MSMM with predicted baseline mRS did not include baseline NIHSS because baseline
severity is already accounted for. The shift analysis was also not adjusted for baseline
severity as the test does not accommodate continuous covariates. Shift analysis for the
NINDS t-PA data was previously repeated for different stratifications of the NIHSS and
the results are reported elsewhere [7].
5.3 Results
The analysis presented in this section is based on 619 subjects that had mRS scores
recorded at 90 days. The raw 90 day mRS outcome distributions for the placebo and t-PA
groups are presented in Table 5.1. There are slight differences in the results presented in
this section compared with other re-analyses of the trial because the raw observed values
are used rather than the intent to treat imputation.
Table 5.1. NINDS t-PA 90 day mRS Counts (%).
0
Control
Treatmen
t
Total

33
(5.3)
57
(9.2)
90

1
50 (8.1)
74
(12.0)
124

2

3

4

5

6

Tota
l

37
(6.0)
23
(3.7)
60

45
(7.3)
40
(6.5)
85

61
(9.9)
42
(6.8)
103

21
(3.4)
19
(3.1)
40

63
(10.2)

310

54 (8.7)

309

117

Figures 5.2 and 5.3 display mRS scores over time for the control and t-PA groups,
respectively. These plots, called Sankey plots, show the percentage of subjects with each
mRS score at each follow-up visit as well as the change in the number of subjects with
each score over time [74]. The longitudinal bar chart shows the percentage of subjects
with each mRS score at each visit. The bands connecting the bars, or the links, represent
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Figure 5.2. Sankey plot of NINDS t-PA control group subjects mRS scores over time.

Figure 5.3. Sankey plot of NINDS t-PA treatment group subjects mRS scores over time.
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the change in the number of subjects in each state, over time. A thicker link is indicative
of more subjects transitioning between the two states. In the 90 day mRS alone, there are
differences between the groups across the entire ordinal scale that are ignored in a
traditional dichotomized analysis. The use of one follow-up visit also results in a loss of
information as there are differences in the distribution of the mRS as well as the
transition rates over the entire follow-up period. Additionally, the inclusion of the
predicted baseline mRS allows one to observe the differences in the transition rates
between treatment groups in the crucial window immediately following randomization
and during the acute treatment phase. All of these differences can be measured and
described using MSMMs and are not accounted for using other ordinal data analysis
methods.
In the general MSMM (Figure 5.1), some of the parameters estimated were close
to zero. Specifically, the transition intensities to death from mRS = {0,1, 2,3} were all
very small. When there is not enough information from the data on certain transition
rates, more intensities may need to be set to zero [4]. Thus, the general model was
reduced, no longer allowing death from any state. Constraints were imposed such that
death is only allowable from mRS = 4 or mRS = 5.
The results from all methods are presented in Table 5.2. The results are consistent
with previously reported re-analyses of the NINDS t-PA data with minor, insignificant
differences in estimates due to the adjustment for the NIHSS and the use of the raw mRS
data versus intent to treat [11, 46, 53, 94, 102]. Table 5.3 presents a review of the
interpretation of the summary statistics obtained from each of the methods of analysis.
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Table 5.2. Results from previously used methods for analysis of the mRS.
Method
Outcome Measure
Summary Statistic
(95% CI)
Logistic regression mRS at 90 d (0-1 vs. 2OR = 2.04
(1.39, 2.99)
6)
Linear regression
mRS at 90 d
Diff. in means =
(continuous)
0.50
Shift analysis
mRS at 90 d
POM
mRS at 90 d
OR = 1.41
(1.01, 1.81)
PPOM
mRS at 90 d
OR =
(linear trend)
1-6 vs. 0
1.88
(1.14, 2.61)
2-6 vs. 0-1
1.67
(1.12, 2.21)
3-6 vs. 0-2
1.48
(1.05, 1.90)
4-6 vs. 0-3
1.31
(0.93, 1.69)
5-6 vs. 0-4
1.16
(0.77, 1.55)
6 vs. 0-5
1.03
(0.61, 1.45)
ACAT
mRS at 90 d
OR =
1 vs. 0
1.12
(0.64, 1.97)
2 vs. 1
2.35
(1.25, 4.44)
3 vs. 2
0.70
(0.36, 1.38)
4 vs. 3
1.30
(0.73, 2.32)
5 vs. 4
0.79
(0.38, 1.66)
6 vs. 5
1.08
(0.52, 2.21)
Logistic regression mRS at 90 d (0 if NIHSS OR = 1.61
(1.13, 2.28)
of sliding
is 1-7, 0-1 if 8-14 and 0dichotomy
2 if >14)
Linear regression
UW-mRS at 90d
Diff. in means =
of UW-mRS
0.08
Repeated measures mRS at 7-10, 90, 180
OR = 1.89
(1.36, 2.63)
GEE
and 360 d (0-1 vs. 2-6)
Repeated measures Predicted mRS at
OR = 1.78
(1.33, 2.38)
GEE (with
baseline and mRS at 7baseline)
10, 90, 180 and 360 d
(0-1 vs. 2-6)
MSMM
mRS at 7-10, 90, 180
Hazard Ratio =
(without baseline) and 360 d
01
0.72
(0.40, 1.30)
12
0.46
(0.23, 0.93)
23
3.04
(0.98, 9.41)
34
0.71
(0.34, 1.49)
45
0.90
(0.36, 2.23)
46
0.98
(0.50, 1.91)
56
1.69
(0.97, 2.95)
10
0.99
(0.60, 1.64)
21
1.03
(0.63, 1.70)
32
1.58
(0.64, 3.92)
43
0.99
(0.64, 1.53)
54
0.58
(0.32, 1.05)
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p
0.0003
0.0073
0.0017
0.0172
0.0017

0.0163

0.0080
0.0175
0.0002
0.0001

0.0533

Piecewise MSMM
(with baseline)

Predicted mRS at
baseline and mRS 7-10,
90, 180 and 360 d
01
12
23
34
45
46
56
10
21
32
43
54

Hazard Ratio =
0.73
0.51
1.29
0.67
0.88
0.96
1.20
1.00
1.14
0.99
1.09
0.80

0.0018
(0.43, 1.23)
(0.28, 0.90)
(0.66, 2.52)
(0.38, 1.17)
(0.53, 1.48)
(0.55, 1.66)
(0.75, 1.92)
(0.62, 1.62)
(0.71, 1.83)
(0.59, 1.68)
(0.72, 1.65)
(0.52, 1.23)

The results of the MSMM are presented as hazard ratios that estimate the effect of the
covariate on transition intensities. A hazard ratio above one signifies a positive
association between treatment and the rate of transition, whereas a hazard ratio of one
implies no effect.
In the MSMM with baseline mRS, treatment with t-PA significantly reduced the
transition intensity between mRS = 1 and mRS = 2 with a hazard ratio of 0.51 (95% CI:
0.28, 0.90). None of the other hazard ratios were significantly different from one. This
finding is consistent with the results of the ACAT model where the only significant OR is
the one comparing mRS category 2 to mRS category 1. The conclusion drawn from the
ACAT is that the most relevant impact of t-PA is to reduce the odds of observing a
category 2 versus a category 1 at 90 days [46]. The results from the MSMM allow for a
more refined conclusion- the most relevant impact of t-PA is to reduce the hazard of
transitioning from mRS category 1 to mRS category 2. Therefore, the t-PA is more
protective of worsening from category 1 rather than promoting improvement from
category 2, which is a distinction that cannot be made from the ACAT results.
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Table 5.3. Summary of statistics obtained from each type of analysis of the mRS.
Method
Statistic(s)
Interpretation
Logistic regression OR
The odds of good outcome in the
treatment group versus placebo
Linear regression
Difference of means
Improvement of the average mRS score
in patients that received treatment
Shift analysis
Probability value
The treatment group shifted in a
(no effect size or OR)
favorable direction toward a better mRS
score versus placebo
POM
Summary odds ratio
The odds of a lower mRS the treatment
group versus placebo
PPOM
ORs for six possible
Treatment has a significant benefit for
dichotomizations of
certain definitions of good outcome
mRS
ACAT
ORs the six adjacent
The treatment group is more likely to
categories of response
have smaller mRS for certain adjacent
mRS scores
Logistic regression OR
The odds of good outcome (defined by
of sliding
baseline severity) in the treatment group
dichotomy
versus placebo
Linear regression of Difference of mean
Improvement of the average utility
UW-mRS
utility scores
score in patients that received treatment
Repeated measures OR
The odds of good outcome over the 12GEE
month period in the treatment group
(dichotomized)
versus placebo
MSMM
Hazard ratios for each
The hazard (instantaneous risk) of
allowable transition
transitioning from one mRS state to
another in the treatment group versus
placebo

5.4 Discussion
It is not realistic to choose one analytic method that is most appropriate for the mRS for
all studies because the efficiency varies depending on the expected distribution of the
treatment effect [3]. In general, ordinal approaches are more efficient when treatment
effects are distributed over the entire outcome range or when the distribution of treatment
effect could not be prespecified [3]. Therefore, it is important to know what the expected
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result of intervention is in the design and sample size calculation stage of a trial. In
comparison, dichotomous approaches are more efficient than ordinal approaches when
treatment effects cluster at single-state transitions and can be specified in advance [102].
However, it is uncommon for clustering to be predictable. If the clustering cannot be
predicted, an ordinal approach should be used.
In this paper, the dichotomized methods were found to be most statistically
efficient with respect to power for the NINDS t-PA trial, and inclusion of predicted
baseline mRS improved the ability to detect a treatment effect in the repeated measures
analysis. The treatment effect clustered at the transition from mRS category 1 to mRS
category 2. If limited information were available in the planning stages for this trial to
confidently predict that the treatment effect would be clustered at that transition, it would
have been worthwhile to consider an ordinal approach. Acute stroke trials are challenging
to conduct as there are few centers that can recruit many patients in the early time
window required for treatment [2]. Because of the low recruitment rate and cost
associated with conducting acute stroke trials, inefficient statistical tests must be avoided
to protect from being underpowered.
Of the approaches that do not rely on the strict dichotomy, the PPOM and MSMM
with predicted baseline were the most efficient. The PPOM and MSMM were found to be
more efficient than linear regression, responder analysis, shift analysis and the UW-mRS
for analysis of the NINDS t-PA data. The PPOM is represented by ORs for the six
possible dichotomizations of the mRS. The first three ORs are significantly different
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from one indicating that treatment has a significant benefit whether 0, 0-1 or 0-2 is
defined as good outcome.
Construction of MSMMs provides a more comprehensive view of the disease
process and allow for exploration of how covariates affect the movement of the process.
The obvious benefit to using the MSMM is the ability to handle progression and recovery
simultaneously by estimating transition rates for both. Because of this, the MSMM allows
for identification of where the treatment effect has the greater impact. Here the effect of
treatment was greatest in reducing the hazard of transitioning from mRS category 1 to
mRS category 2. A more clear understanding of the effect of treatment could also be
beneficial in identifying characteristics of subjects that are more likely to benefit or
experience harm from a therapy.
Another benefit of MSMMs is the potential for decreased sample size. The power
of MSMMs applied to acute onset clinical trial data was shown to increase significantly
when the number of follow-up visits was increased [93]. Future trials could collect the
mRS more frequently, increasing the power to detect differences using this modeling
technique. This would be a more cost-effective than recruiting more subjects to increase
power as the telephone assessment of stroke disability with the mRS is reliable in
comparison with a face-to-face assessment [103].
The MSMM results in a more comprehensive understanding of treatment effect;
however it also increases the difficultly to determine the sample size to adequately power
a study using this analysis. Without a summary statistic of effect size, the implementation
of these models in the analysis of the primary outcome in trials requires quite a bit of
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foresight on the expected distribution of the effect of a therapy or treatment. However,
once the distribution of expected treatment effect has been specified simulation-based
power analysis for these models is straightforward. Another limitation of MSMMs is the
increasingly computationally intensive nature as covariates and time-varying intensities
are added to the models.
Future directions of this research may include development of a software package
to automate the baseline mRS prediction. The package could include more complex
methods for estimation, potentially Bayesian PCA. Another feature of the package could
be assistance with data manipulation required to use the msm package in R to fit the
MSMMs (eg. wide to long format and incorporating exact time of death). In addition, a
package could be developed to streamline the simulation-based power analyses.
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6 Overall Discussion
6.1 Specific Aims Revisited
The aims of this dissertation are:
1. To explore the operating characteristics (type I error and power) of MSMMs
compared with repeated logistic regression used to analyze sparsely populated
repeated measures ordinal data.
2. To develop a MSMM approach with piecewise-constant transition intensities that
incorporates a latent baseline state.
3. Analyze acute stroke therapy trial data using the methods developed in Aim 2 and
compare the results with those from alternative methods previously suggested for
the analysis of the mRS.
6.2 Summary and Conclusions
This work focuses on the use of MSMMs to analyze sparsely populated and
longitudinally collected ordinal data. The mRS score from acute stroke therapy trials was
the motivating example. To determine whether MSMMs were feasible as an analytic
method for sparsely populated ordinal data, the operating characteristics are investigated
using simulation studies in Aim 1. Results indicate that MSMMs can be a more efficient
approach than repeated measures logistic regression to analyze sparsely populated ordinal
data. There are also situations where dichotomization might not lose efficiency and may
be more powerful than the MSMM. Depending on the observed data structure and
treatment effect distribution, either method could be more powerful. Results also show
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that increasing the number of follow-up visits can dramatically improve power to detect a
treatment difference. Thus, we recommend that future acute stroke therapy trials collect
the mRS more frequently, increasing power to detect treatment group differences.
Increasing the frequency of outcome collection could be more cost-effective than
recruiting more subjects since the telephone assessment of the mRS is as reliable as the
face-to-face assessment [103].
Given that the MSMM is an approach that could realistically analyze sparsely
populated ordinal data, a latent baseline estimation procedure is developed in Aim 2.
Methods that analyze only one time point have traditionally adjusted for baseline severity
using the NIHSS score because the mRS score is not available at baseline. When
modeling data longitudinally, the transition from baseline to first follow-up is important
because much of the progression or recovery experienced by a patient suffering from an
acute onset disease is expected to occur early on. Inclusion of the latent baseline in a
piecewise-constant MSMM improves efficiency to detect a treatment effect as compared
to the MSMM without baseline that adjusted for baseline NIHSS.
In the application to the NINDS t-PA trial in Aim 3, the MSMM with baseline has
proven to be an efficient method of analysis, as compared to many of the other popular
methods for the mRS. While dichotomized analysis is the most powerful for this
particular data set, for most trials, prediction of the clustering of treatment effect a priori
is not realistic. If the treatment effect clustering is predicted incorrectly, the dichotomized
statistical test becomes inefficient. For trials where the treatment effect is expected to be
distributed over the entire range of the outcome or when the clustering cannot be
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predicted, methods that analyze the full ordinal scale should be used [3]. The MSMM
with estimated baseline is comparable in efficiency to the PPOM and the two methods
outperform the other ordinal methods. The MSMM allows for direct identification of
where the treatment effect is most significant and the PPOM does not.
The goal of this dissertation is to lay the foundation for the use of MSMMs in
practice to analyze ordinal data, specifically data from acute stroke therapy trials. We
conclude, from the example presented, that the MSMM with latent baseline mRS is as
efficient, if not more, than other methods currently used to analyze acute stroke therapy
trial data. A limitation of this work is that comparison of efficiency of other methods is
only done for data from one trial. The “best” method for analysis of the mRS will change
depending on the distribution of the treatment effect. Thus, future work should consider
data from other trials to better understand the comparative efficiency of the MSMM.
This work supports the use of MSMMs for acute stroke therapy trial but
immediate implementation of these models for the primary analysis of new studies is
likely not feasible because of lack of readily available software to design a study that uses
MSMM analysis. The MSMM is a great tool to identify the finer details of the treatment
effect but the complexity of the model makes determination of sample size needed to be
adequately powered to detect a treatment effect difficult. Future work would explore how
to appropriately power a new study using MSMM. Without a summary statistic of effect
size, the implementation of these models in the analysis of the primary outcome in trials
requires foresight on the expected distribution of the effect of a therapy or treatment.
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However, once the distribution of expected treatment effect has been specified
simulation-based power analysis for these models is straightforward.
Additional future directions of this research include development of a software
package to automate the baseline mRS estimation. Another feature of the package could
be assistance with data manipulation required to use the msm package in R to fit the
MSMMs. Finally, the package could also contain functions to streamline the simulationbased power analysis that was used in Aim 1.
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